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ABSTRACT 
 
Parkinson’s disease is the second common neurodegenerative disease and is most frequently 
diagnosed in individuals over 60. There are no available medications that can prevent or restore 
the loss of neurons that correspond to motor impairments in patients. Identifying novel therapeutic 
compounds that are capable of slowing and reversing the extensive neurodegeneration that occurs 
in PD remains an important goal of the field. While basic research has identified potential 
therapeutic agents, studies often use young model organisms to demonstrate efficacy of the target 
compound. This approach ignores the impact of the aged CNS on the disease process, and likely 
contributes to high failure rates of translation in clinical trials. Here we investigate the capacity for 
astaxanthin (AXT), a xanthophyll carotenoid, to attenuate the neurotoxicity to MPTP, a toxin 
routinely used to establish parkinsonian symptoms in mice. We show that AXT reduces MPTP 
induced neurotoxicity in young, but less effective in the aged animals. While AXT is an interesting 
neuroprotective capacity, there are also multiple reports that indicate AXT may preserve cognitive 
function in the context of neurodegeneration and neural injury, the impact of AXT under 
physiological conditions and in the aged CNS has been largely uninvestigated. We also evaluate 
the effect of AXT on cognitive function in young and aged mice. Here, we show that AXT 
supplementation can modulate neural plasticity is associated with improved performance in 
cognitive behavioral tasks. This diet effect was observed in both young and aged mice, suggesting 
a novel and direct mechanism of action in synaptic function.  
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Chapter 1 
Introduction  
 
NOTE TO READERS: Portions of this chapter of been previously published in the journal of 
Geroscience (GeroScience (2017) 39:19–32) and Brain Science (Brain Sci. 2016 Sep 23;6(4)) and are reproduced with 
kind permission from the American Aging Association and MDPI respectively. 
 
PARKINSON’S DISEASE 
 
Parkinson’s disease (PD) is the second most common neurodegenerative disorder 
characterized by motor dysfunctions including, bradykinesia, rigidity of the limbs and a shuffling 
gait. According to the Parkinson’s Disease Foundation, it is estimated to afflict 10 million people 
worldwide, and is associated with a dramatic economic burden. Furthermore, PD is projected to 
become more prevalent as the largest sector of the US population gets older [1]. Currently, the 
commonly prescribed medications initially improve motor symptoms, although the efficacy is 
temporary and patients often suffer from ‘wearing off” effects as disease worsens. There are still 
no medications available to stall the progression of the disease or restore the degeneration that has 
already occurred; therefore there is a critical need to identify compounds useful for modulation of 
the disease process and prevention of symptoms among these patients. 
Parkinson’s disease is primarily characterized neuroanatomically by the degeneration of the 
neurons in the substantia nigra pars compacta (SN), resulting in a substantial loss of dopamine 
(DA) afferents to the striatum and subsequent motor impairment. It is estimated that nearly 50% 
of dopaminergic cells in the SN have been lost prior to clinical presentation of motor dysfunction. 
It is now understood that PD pathology extends to extra nigral regions including the locus 
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coeruleus, nucleus basalis of Meynert, peduculopontine nucleus, intralaminar thalamus, and lateral 
hypothalamus, suggesting dysfunction and neurodegeneration in many areas of the brain [2]. It is 
histopathologically characterized by the formation of Lewy bodies, intraneuronal protein 
inclusions comprised predominantly of α-synuclein (-syn). These protein aggregates have been 
observed throughout the brain, and pathological -syn deposition is thought to begin in the medulla 
and spread throughout the midbrain to cortical regions in a manner that corresponds to the onset 
of clinical symptoms [2]. These protein aggregates are associated with microgliosis [3], and 
impaired cellular physiology, although the precise mechanisms leading to cytotoxicity are 
currently unknown. Furthermore, there are several non-motor symptoms that frequently occur in 
PD that are often severe and significantly impact quality of life of the patients. These include 
autonomic nervous system dysfunction, sleep abnormalities, mood disorders and cognitive 
dysfunction. While these symptoms are far less characterized and understood than the classical 
motor symptoms, it is thought that this cluster of symptoms is mediated by dysfunction in other 
neurotransmitter systems including serotonin and acetylcholine [4].  
The vast majority of Parkinson’s disease cases are classified as idiopathic, however, 
approximately 5% of PD cases are genetically linked. There are several gene mutations that confer 
susceptibility or are associated with the development of PD, including mutations in leucine-rich 
repeat kinase (LRRK), PTEN-induced kinase 1 (PINK1), and the protein deglycase, DJ1. 
However, α-syn has proved to have a very strong association and relevance to PD and similar 
disorders collectively known as synucleinopathies. Abnormalities in the SNCA gene that encodes 
the α-syn protein are strongly correlated with the development of an autosomal dominant familial 
form of PD [5]. Multiplications of the SNCA gene are known to increase the expression of the α-
syn protein, whereas certain missense mutations of the gene (A53T, A30P, E46K) produce variants 
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of α-syn, both of which have known pathological attributes related to the increased propensity to 
aggregate. Furthermore, there are a few environmental factors that are also thought to increase risk 
of developing Parkinson’s disease. According to the Parkinson’s Disease Foundation, these 
potential risk factors include exposure to certain toxins and pollutants like paraquat and other 
pesticides, heavy metals, and industrial solvents and chemicals like polychlorinated biphenyls. 
Experimental models of PD have been developed from these risk factors and are broadly 
categorized into genetic based or toxic models. Genetic based models include transgenic mice 
lacking or over expressing PD related genes like SNCA, LRRK1 or PTEN, or genetic expression 
can be manipulated with gene delivery techniques like viral vectors. Toxic models employ 
compounds that ultimately induce neurodegeneration, although delivered in a variety of ways.  
These models are variable in recapitulating the pathological features of PD and each is associated 
with unique caveats; therefore the most suitable model is dictated by the experimental end points.  
The Interaction with aging  
Aging is a major risk factor for the development of PD [6], evidenced by the fact that the 
incidence increases for every decade over 50 years of age. While aging contributes to PD, it is also 
underrepresented in PD research, as it is common for the experimental models to be carried out 
using young animals. However, the impact of aging is essential to consider in terms of the disease 
process because many of the physiological changes that occur in aged animals can drive or 
exacerbate the pathological mechanisms that lead to PD and alter both the course and tempo of the 
disease.  
The impact of aging on the incidence of PD is compounded by the fact that the dopaminergic 
neurons of the SN seem to have a unique vulnerability to cellular stressors in the microenvironment 
[6]. Although it is not completely understood what sets these cells apart from those of other DA 
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pathways, the neurons of this nucleus are more susceptible to the homeostatic disturbances and 
degenerate significantly more compared to similar or adjacent regions [7]. This can be grossly 
attributed to high oxidative stress and inflammation. It is known that the SN is exposed to higher 
levels of oxidation compared to other dopaminergic centers [8]. This is partly due to an unusually 
high concentration of iron, which through the Fenton reaction, can generate free radicals, as well 
as nitric oxide released by microglia that densely populate this region [9, 10]. In addition to the 
accumulation of reactive oxygen and nitrogen species, the SN is also ill-equipped to neutralize 
them, due to a low expression of glutathione, an important endogenous antioxidant molecule, 
leading to an inevitable increase in oxidative stress [11]. Aging is also associated with increased 
levels of oxidative stress and altered microglial function and this combined with the SN’s reduced 
resilience to ROS could promote neurodegeneration.  
The role of neuroinflammation in PD is also particularly important in the context of aging. 
Inflammation is known to increase with age. This is largely attributed to the age related changes 
in microglial physiology. Microglia, myeloid derived macrophages, are the resident immune cell 
of the CNS and constitute 10% of the cell population. Their highly ramified processes are highly 
motile and constantly survey parenchyma, facilitating the detection and the cellular response to 
infection and injury. However, microglia are also involved in many homeostatic functions and are 
now known to be highly active during post-natal synaptic pruning and synaptic plasticity [12, 13].  
Microglia are known to undergo a phenomenon known as priming with age. This describes a 
propensity for microglia to attain a pro-inflammatory state and is characterized by 4 principal 
features. 1) Primed microglia will exhibit higher levels of inflammatory mediators and surface 
makers even in the absence of immune stimulation. 2) Microglia also demonstrate hyperactivity 
upon subsequent activation where they release exaggerated amounts of cytokines and reactive 
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oxygen/nitrogen species. 3) They are also resistant to regulatory mechanisms that typically restore 
microglia back to their inactivated state, causing them to remain in an aggravated state for a longer 
period of time [14] 4) and do not respond to stimuli, such as IL4, that promote anti-inflammatory 
factors,  and  secretion of neurotrophic and angiogenic factors [14] [15] [16]. For example, this 
phenomenon of microglial priming was demonstrated empirically by Lee, Ruiz et al. (2013). These 
authors induced microglial activation in the brains of young and old mice with the application of 
a cytokine cocktail designed to elicit an M1, pro-inflammatory phenotype (IL1 + IL12) or an 
anti-inflammatory, M2 phenotype (IL-4 + IL-13). This study confirmed that pro-inflammatory 
factors elicit an increased response in microglia from the aged brain, while the same aged cells 
were less responsive to the factors associated with M2 phenotype [15].  
 In order to elucidate the molecular underpinnings of the age-related alterations in microglial 
function, researchers have begun to assess the differential expression of genes and proteins in 
primary microglia.  One recent study has identified a microglial “sensome” to describe a range of 
compounds that stimulate microglia and how these responses change with age. This research 
employed RNAseq to compare the transcriptional profiles of isolated microglia to whole brain as 
well as microglia isolated from aged animals to further assess how the microglial sensome may 
change with age [17]. These authors demonstrated that many of the genes related to sensing 
endogenous ligands were down regulated, such as those released during neurodegeneration. 
However, genes pertaining to the detection of infectious agents were up-regulated. Furthermore, 
another recent study using gene microarrays of isolated microglia identified an up-regulation of 
NFB related genes in these aged cells [18]. Sustained microglial activation and microglial 
priming can perpetuate neurodegeneration by increasing cellular stress both from enhanced release 
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of cytotoxic substances, but also from the loss of trophic support as a result of impaired microglial 
homeostatic function.  
 Role of Neuroinflammation 
The precise pathophysiology that precipitates the development of PD is unknown, although it 
is understood that a few key biological processes are often impacted in patients, including 
mitochondrial function, proteostaisis, immune function leading to oxidative stress and 
inflammation. Neuroinflammation is critical factor in the disease process that clearly contributes 
significantly to the neurodegeneration seen in PD. However, it is difficult to ascertain if 
inflammation initiates pathological features of PD, or is triggered by the widespread protein 
aggregation and neuronal death that occurs during disease progression. McGeer et al. (1988) 
described the presence of increased reactive gliosis and infiltrating T-cells around the SN in post 
mortem analysis of PD brains [19]. Their observations provided some of the first indication that 
increased neuroinflammation is associated with DA cell death. Many other studies have reported 
features of inflammation in post-mortem samples, such as increased levels of inflammatory 
mediators like iNos and Cox-2 [20], supporting the contribution of increased neuroinflammation 
during advanced stages of the disease. Similar patterns of activated microglia have been detected 
in the brain areas associated with clinical symptoms of the disease [21]. Interestingly, this 
distribution of gliosis was evident in both newly diagnosed patients and those with advanced 
pathology. Elevated levels of pro-inflammatory cytokines have also been detected in the 
cerebrospinal fluid and plasma of PD patients at early stages of the disease. These findings suggest 
that microglial activation may be initiated in early stages and remain an ongoing process 
throughout the disease. Furthermore, inflammatory insults and injuries are known to increase the 
risk of developing PD. Traumatic brain injury (TBI) have been linked to an increased risk of 
7 
 
developing the disease in a frequency and severity dependent manner; multiple injuries, or injuries 
requiring hospitalization were more strongly correlated with PD onset [22]. This occurrence is 
largely attributed to the neuroinflammatory cascade that follows trauma. Certain infections causing 
neuroinflammation have been known to lead to a post-encephalitic Parkinsonism. This may be 
because the SN is densely populated by microglia [23], rendering it is especially susceptible to 
inflammatory stimuli. For example, intracranial injections of lipopolysaccharide (LPS), a bacterial 
antigen, dramatically activate microglia and leads to nigrostriatal degeneration and motor 
symptoms of PD [24]. Parkinsonism is a separate condition distinct from PD, however these 
observations of inflammatory insults leading to cell death may have important implications for PD 
itself. Taken together, these data suggest a potential role of neuroinflammation in ongoing cell 
death that occurs in PD. 
Furthermore, as the presence of abnormal α-syn is a major feature of PD, it is important to 
also note that the pathological forms of this protein are associated with microglial activation in the 
brains of PD patients and this observation is consistently recapitulated in animal models. The 
presence of α-syn aggregates in the brain can stimulate glial activity, often eliciting the release of 
inflammatory mediators. [25]. The nitration of α-syn is a common modification associated with 
pathology thought to be promoted in an oxidative environment. Stimulation of microglial cells 
with nitrated and aggregated α-syn alters the cellular morphology and transcriptional profile to a 
pro-inflammatory phenotype, with increased transcription of IL-1β, TNF-α, and IFN-γ, as well as 
induction of NF-B signaling [26]. It is thought that this inflammatory response to abnormal α-
syn will perpetuate neural dysfunction through the release of cytotoxic compounds that leads to 
cell death. Many of these studies were done using either glial cell lines or in young animals, 
neglecting the impact of the pro-inflammatory actions of -syn within the primed glial 
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environment of an aging brain, thus causing even more damage. In fact, when -syn is introduced 
into an aged animal it is more cytotoxic compared to the young controls [27], again highlighting 
the importance of the pathological processes that underlie PD and their interaction with aging. 
ASTAXANTHIN 
Carotenoids are a large class of compounds synthesized in plants and certain photosynthetic 
microorganisms. Many carotenoids are directly involved in photosynthesis, while others are 
produced as a means of protecting these species from photo oxidation and related damage. They 
are typically red, orange or yellow pigments thus found in fruits and vegetables of these colors as 
well as leafy greens. Many carotenoids have been identified in nature, however far less are 
consumed and reach detectable levels in serum and tissues, and only some of which can be 
converted to vitamin A in humans. Carotenoids are further subdivided into carotenes and 
xanthophylls; the latter are disguised by the presence of oxygen at the end of the polyene chain. 
Carotenoids have been intensely investigated for their role in human health, and it has been 
suggested that certain carotenoids can generally promote health and reduce risk of developing 
various diseases, including cancer, cardiovascular disease and hypertension [28, 29].  
One carotenoid that has gained significant interest in recent years is astaxanthin (AXT). AXT, 
a xanthophyll carotenoid, is being investigated individually in a broad range of clinical 
applications, including cardiovascular health, metabolic syndrome, treatment of gastric ulcers, and 
cancer, all of which have elements of inflammation and/or oxidative stress in their pathogenesis 
[30]. AXT is already approved as a dietary supplement and is widely available commercially. To 
date, there are no significant adverse effects attributed to AXT supplementation, indicating that 
this is both a cost effective and relatively safe compound. It has also been shown to cross the blood 
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brain barrier and is detectable in the brain tissue [31]. These characteristics make AXT a desirable 
candidate for further investigation to elucidate its therapeutic potential. 
 AXT is produced by the marine algae Heamatococcus pluvialis or synthetically derived from 
carotenoid precursors and used commercially to feed to farmed fish species to increase 
pigmentation. Astaxanthin has many suggested mechanisms of action, many of which seem to 
uniquely oppose pathophysiology that underlie Parkinson’s disease. For example, AXT has been 
observed to exert an anti-inflammatory action, as well as induce moderate improvements in some 
aspects of mitochondrial function. Taken together, preliminary observations indicate a distinct and 
promising therapeutic potential in the treatment and management of symptoms in PD patients [32-
34].  
Furthermore, because interest in investigating the therapeutic potential of this compound has 
increased steadily over the past few years, it has been tested in the context of diverse disease 
models. Findings from recent reports suggest that AXT may also be a useful neuroprotective agent 
in other neurodegenerative disorders in addition to Parkinson’s disease. Cognitive dysfunction is 
a common and severe symptom of neurodegeneration. Emergent evidence from recent studies also 
implicates AXT as useful in mitigating cognitive dysfunction in pathological conditions like 
neurodegeneration and neural injury, but also may have a role in modulating cognitive decline 
associated with aging [35-39].   
 AXT as a potential therapeutic agent in the treatment of PD 
As discussed above, the SN is exposed to high levels of oxidative stress relative to other areas 
of the brain due to innate features of the neurons that comprise this region [40]: 1) high 
concentration of iron leads to the production of free radicals through the Fenton reaction and 3) 
low levels of glutathione [41]. Glutathione activity in this region declines with age, further 
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reducing the capacity to manage the accumulation of ROS in the SN. Taken together, these 
characteristics create an environment of high oxidative stress that can impair neuronal function.  
AXT has potent and diverse actions as an antioxidant and is reported to be several times more 
effective than other carotenoids in its class. The molecular structure of AXT allows it to reduce 
free radicals in a variety of ways, including absorbing them into the carbon backbone, donating 
electrons and forming adducts with the reactive species. Although xanthophyll carotenoids are 
structurally similar, the presence of polar ionone rings at either end of the AXT molecule. The 
configuration allows the molecule to span across the phospholipid bilayer of cell membranes and 
protect the membrane against lipid peroxidation [42].  
There is substantial evidence indicating that treatment with AXT causes a reduction in the 
markers of cellular stress due to excess ROS production, such as 8-isoprostane, protein carbonyl 
moieties and 8OHdG [43]. Additionally, AXT has been shown to increase the efficacy of 
endogenous antioxidant mechanisms in vivo including increasing the expression or activity of 
glutathione, catalase, thioredoxin reductase and superoxide dismutase (SOD) [44, 45] . It has also 
been shown to upregulate heme-oxygenease 1 (HO-1) through increase in NRF [46, 47]. These 
findings suggest that AXT treatment may help alleviate some of the ongoing oxidative stress that 
occurs during the progression of PD as it contributes to cellular dysfunction.  
However, in addition to oxidative damage, there are a number of physiological changes 
that occur with age that exacerbate the cellular stress in the SN. Mitochondrial dynamics, 
proteosomal efficiency [48] and levels of synuclein [49] are all altered with age, likely rendering 
the DA cells more vulnerable to neurodegeneration. As mentioned previously, aging also leads to 
microglial priming and may facilitate PD disease progression. Chronic microglial activation results 
in prolonged exposure to cytotoxic, pro-inflammatory cytokines, increasing cellular stress and 
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ultimately leading to neurodegeneration [50]. Age induced primed microglia are hyperactive upon 
subsequent stimulation and release exaggerated amounts of cytokines. They are resistant to revert 
back to a state of tissue repair and maintenance of homeostasis, as they are less responsive to 
regulatory mechanisms [15]. 
Given the range of pathological mechanisms involved in neurodegeneration seen in PD, 
AXT seems to have a unique potential for the treatment of this disorder. Many diverse biological 
activities have been described in the literature that are particular relevant to that pathophysiology 
of PD, as well as normal aging. Based on this knowledge, the interaction of aging and parkinsonian 
symptoms should be responsive to treatment with AXT. For example, AXT has also been 
implicated in modulating microglial activity. Experiments using astaxanthin to treat a transformed 
microglial cell line can reduce the expression of IL-6 and iNOS/NO in vitro when exposed to an 
immune stimulus such as LPS [51]. These results were corroborated by other studies using aged 
animals where astaxanthin reduced the release of nitric oxide [43]. These molecules are released 
in high amounts by activated microglia and are associated with neuronal damage; attenuating the 
output of inflammatory mediators with astaxanthin may offer some neuroprotection from the 
inflammatory cascades occurring in the SN. 
Some authors have reported alterations in mitochondrial function after AXT treatment. 
Although most of these studies were conducted in vitro, this is of great interest to the treatment of 
PD. Mitochondrial dysfunction has been implicated in the etiology of the disorder evidenced by 
the common toxins that induce Parkinsonism. Both MPTP and rotenone are used to produce 
Parkinson’s models by selectively targeting mitochondria leading to the death of SN neurons. 
Multiple genetic mutations of proteins involved in mitochondrial dynamics have been clearly 
linked to the development of familial Parkinson’s. Furthermore, some of these mitochondrial 
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proteins are associated with a loss of function with age, and may contribute to the increased 
incidence of diagnosis over the lifespan.  
Furthermore, it has been demonstrated recently that mitochondria are a significant source 
of oxidative stress not only in these DA neurons, but also in additional nuclei known to degenerate 
in PD. For example, both the locus coeruleus and SN express L-type calcium channels that allow 
for an extraneous calcium influx that taxes the mitochondria [52]. The presence of these channels 
and their associated calcium burden has been proposed to be a common physiological feature that 
contributes to the cellular vulnerability for the brain regions affected in PD. Attenuating this 
mitochondrial derived oxidative stress that results from calcium overload has been the lead to the 
use of calcium channel antagonists for the treatment of PD [53]. These dihydropyrdines, 
specifically israpidine, have been shown to be tolerable and safe among PD patients are now in 
aPhase III clinical trial [54]. 
  The success of these drugs lends support for the therapeutic use of AXT as well. There is 
empirical evidence to suggest that AXT works at the level of the mitochondria. According to HPLC 
analysis of cellular fractions, AXT will accumulate in mitochondria, and has the capacity to 
increase mitochondrial activity as indicated by increased respiration and mitochondrial membrane 
potential (MMP) [55]. Mitochondrial dysfunction is a common pathophysiological observation in 
PD, and is recapitulated in the both MPTP and synuclein model. It has been shown that treating 
isolated mitochondria with α-synuclein oligomers induced mitochondrial dysfunction by inhibiting 
complex 1 and associated with reduced calcium retention time, release of ROS and induced 
mitochondrial swelling [56]. In specific studies related to PD, AXT has been shown to protect SH-
SY5Y cells from 6-OHDA [33]. Similar studies show that AXT treatment can mitigate MPP+ 
induced cytotoxicity [34, 57, 58]. MPP+ is a toxic metabolite of the dopaminergic neurotoxin 
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MPTP used in experimental animal models of PD. These cell culture results were corroborated by 
an in vivo study using AXT to prevent the neurodegeneration in the SN in response to dose of 
MPTP (1 i.p. dose 30mg/kg daily for 28 days) [34]. This treatment regimen effectively protected 
against the loss of tyrosine hydroxylase in the SN and striatum after chronic exposure to the 
neurotoxin.  However, it is important to understand that many drugs that have been successful in 
some pre-clinical models of PD have failed to translate to patients with PD. Developing and testing 
pre-clinical models that highlight the impact of aging must be considered for future studies. 
 
 Astaxanthin as a potential therapeutic agent for the prevention of cognitive decline in aging 
and other neurodegenerative diseases  
 
 Aging is recognized as a primary risk factor for the development of many neurodegenerative 
diseases. Aging leads to numerous physiological changes that cause loss of tissue integrity and 
loss of function in multiple organ systems. In the aged brain, the age related anatomical and 
physiological changes can compromise cognitive functions including memory, attention, 
executive function and perception, with high variability [59-61]. The molecular mechanisms 
involved in aging of the brain, and how these processes relate to significant changes in some 
cognitive domains and neurodegenerative diseases are still being elucidated. However, it is widely 
accepted that increased inflammation, mitochondrial dysfunction, disrupted calcium homeostasis 
and elevated oxidative stress within the brain all contribute to neuronal dysfunction and cell death 
[62]. Furthermore, incidents of neurodegenerative disease are projected to increase as the largest 
sector of the population grows older, resulting in a greater economic burden. Therefore, developing 
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strategies to manage these deleterious effects of aging is a high priority in the effort to preserve 
cognitive function and hinder the development of neurological pathologies in an aging population. 
Previous sections have discussed the use of AXT within the context of Parkinson’s disease, 
however, AXT has also been tested in models of other neurodegenerative conditions and models  
of neural injury that are known to present with symptoms of cognitive dysfunction, further 
supporting the therapeutic application of AXT in these human diseases. For example, AXT 
successfully reduced neurotoxicity in cell culture models of Alzheimer’s disease (AD). The 
application of AXT in vitro protected PC12 cells from cytotoxicity induced by the amyloid β 
fragments [63]. Wang et al. [64] replicated the previous findings and attributed the observed 
neuroprotection from the amyloid β peptides to the involvement of extracellular signal regulated 
kinase 1 and 2 (ERK1/2) signaling and the downstream activation of HO-1. In these studies, AXT 
ultimately reduced apoptotic related mediators caspase 3, and Bax in PC12 and SH-SY5Y cells, 
respectively. Lobos et al. further demonstrated a neuroprotective action of AXT against amyloid 
toxicity. These authors used AXT to protect primary hippocampal neurons from the generation of 
ROS and calcium dysregulation induced by amyloid-β [65].   
AXT also attenuated the neurotoxicity of chronic exposure to aluminum chloride in 4 
month old Swiss albino mice. 42 days of AXT treatment resulted in fewer oxidized proteins, lipids 
and reduced glutathione. This reduced oxidative stress was also associated with the preservation 
of cognitive function demonstrated by the improved performance on the radial arm water maze, 
an indicator of spatial memory. Interestingly, the deposition of heavy metals including aluminum 
is associated with the pathology of multiple neurodegenerative diseases. These results suggest 
another therapeutic mechanism of AXT intervention in neuropathy and preserving neuronal 
function [37].  
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In a model of epilepsy, AXT lowered seizure activity induced by amygdala kindling and 
reduced neuronal loss in CA3 region of hippocampus of supplemented rats. [66]. These major 
findings were associated with reduced oxidative damage (MDA and ROS output) and reduced 
caspase 3 expression with a concomitant decreased release of mitochondrial cytochrome C into 
cytosol. These observations suggest that AXT may be neuroprotective based not only on the 
capacity to reduce oxidative stress but also indicates an additional action of interfering with 
mitochondrial mediated apoptosis occurring in this model, which ultimately attenuated neuron loss 
in this model. 
Al-Amin et al. [67] demonstrate that AXT administration during early developmental 
period rescued some of the autistic features and behavior deficits induced by prenatal valproic 
acid. The same group [68] also observed that prenatal lipopolysaccharide (LPS) exposure induced 
behavioral abnormalities and oxidative stress were alleviated with 6 weeks of AXT oral 
administration in their adult offspring. These two reports suggest that AXT may play an important 
role in maintaining an optimal environment and redox homeostasis during critical periods of brain 
development in the face of CNS insults.  
Neurogenesis and plasticity significantly decrease with age [69], a trend that also reflects 
a concomitant cognitive decline among some elderly individuals. Efforts to rescue this deficit are 
associated with improved behavioral outcomes in hippocampal dependent tasks and restored 
cognitive function [70]. It is known that neurogenesis and hippocampal plasticity can be stimulated 
(and even negatively regulated) by extrinsic factors including environment, exercise, and diet [71]. 
For example, our lab has successfully used dietary supplements to maintain progenitor cell 
proliferation and neurogenesis in aged animals [72-74], supporting the possibility for natural 
compounds to maintain cognitive function through modulation of neurogenesis.  
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There is emerging evidence that suggests AXT may promote neurogenesis and plasticity. 
Neural progenitor cells (NPCs) are a self-renewing stem cell population that can give rise to new 
neurons that later become integrated into existing circuits of the hippocampus to replace 
degenerating cells. NPCs proliferation is known to slow with aging [69], and promoting stem cell 
proliferation in the DG is regarded as a strategy for maintaining the regenerative capacity of the 
hippocampus and is associated with preserving cognitive function. It has been reported that AXT 
can increase proliferation of neural precursor cells in vitro. Kim et al. [75] show that the application 
of AXT in culture increased the proliferative and colony forming capacity of neural stem cells in 
a time and dose dependent manner, and observed an increase in proliferation related genes like 
cyclin dependent kinase 2 (CDK2). It has been demonstrated that not only can AXT treatment 
promote cell replication, but can also be directly protect NPCs when exposed to an oxidative insult 
(of 0.3 mM H2O2) and limit the subsequent apoptotic cascade [76]. As stated above, oxidative 
damage is known to increase with age, and AXT may help allieviate oxidative stress in the aging 
hippocampus. These in vitro observations of cell proliferation have been corroborated recently in 
young adult mice (11 weeks) treated for 4 weeks with an AXT supplemented diet [77]. This study 
reported an increased immunohistochemical labeling of bromodeoxyuridine (Brdu) in cells in the 
DG of the AXT treated mice, indicating that the AXT enriched diet was able to stimulate cell 
division in the SGZ. These trends of AXT augmented neurogenesis were also associated with 
improved performance on the Morris water maze [38, 77-79], a spatial learning task mediated by 
the hippocampus. This data demonstrates that the therapeutic effects of AXT observed either in 
cell culture and in young animals can lead to functional behavioral outcomes and discernable 
improvement on cognition.  
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Various reports implicate cell growth and differentiation pathways are likely stimulated by 
AXT treatment. A few studies report the capacity for AXT to modulate ERK signaling, further 
supporting a possible role for AXT in cell growth or differentiation and neurogenesis. ERK 
signaling pathway is classically described as part of the mitogen activated protein kinase (MAPK) 
superfamily, a highly studied and conserved group of kinases with numerous downstream receptor 
tyrosine kinases and mitogens. Also, this cell signaling cascade is complex; ERK and related 
proteins are important regulatory molecules that interact with other pathways to integrate signals, 
leading to various end points depending on the biological system [32]. Although it is difficult to 
interpret how this signaling cascade is modulated in an intact organism (in contrast to isolated cells 
in culture), this observation has some interesting implications for protecting cognitive function 
through age. ERK is capable of regulating other pathways, but specifically in neurons it is 
necessary for the induction of long term potentiation. Further, ERK signaling is involved in many 
hippocampal functions and therefore has significant implications for learning and memory. For 
example, blocking ERK signaling can impair recall after water maze training, and impair the 
associative learning in an odor avoidance task. These intricacies have not yet been fully elucidated 
in regards to how AXT is modulating ERK signaling as a regenerative or neuroprotective 
mechanism. While ERK is known to be involved in neurogenesis, there is also some indication 
that AXT induced activation of the ERK pathway may facilitate the release of NRF2, allowing the 
protein to translocate to the nucleus and increase transcription of antioxidant defense mechanisms 
like HO-1. This upregulation of HO-1 was attributed to the cytoprotection from oxidative stress 
caused by exposure to amyloid β, indicating another mechanism through with AXT can reduce 
oxidative stress and protect the CNS [80]. AKT, PI3K and ERK are other commonly reported cell 
signaling cascades that are affected by AXT treatment. These proteins are involved in major signal 
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transduction pathways with known roles in cell growth and differentiation. Xu et al. [38] describe 
changes in these AKT related molecules and attributed this pathway to mediate improved 
performance on the Morris water maze.  
BDNF is decreased with age, and is associated with reduced hippocampal volume and 
corresponding impaired spatial memory in aged humans (59-80 years old) [81, 82].  BDNF is an 
important nerve growth factor that not only promotes neurogenesis but also has a reported role in 
modulating synaptic transmission. While the upregulation of AKT or ERK could be the underlying 
mechanism driving stem cell proliferation in the hippocampus, AXT may also be influencing 
synaptic plasticity though inducing an upregulation in BDNF [81, 82]. Moreover, BDNF can 
facilitate LTP through ERK dependent mechanisms [83].  When ERK is activated by BDNF, it 
can lead to the transcription of genes needed for synaptic plasticity and neurogenesis [81, 84].  To 
date, there is little discussion of either of these processes being influenced by AXT treatment, 
although both synaptic plasticity and neurogenesis decrease with age and are associated with loss 
of cognitive function [85].  
 OBJECTIVES 
The objective of these studies was to determine a therapeutic potential for astaxanthin in age 
related disorders. Based on a plethora of studies spanning various clinical models and model 
organisms that suggest multiple mechanisms of action, we hypothesized that astaxanthin would be 
an effective therapeutic agent in the treatment of both Parkinsonian features and normal age related 
cognitive decline.  Chapter 2 investigates the efficacy of astaxanthin supplementation on reducing 
the neurotoxicity that occur after exposure to MPTP. Chapter 3 compares the efficacy of 
astaxanthin pretreatment in mitigating MPTP neurotoxicity in young and old mice. This is a critical 
experiment in terms of translational value, as many pre-clinical models of neurodegenerative 
diseases use young adult animals. Neurodegenerative disease are often associated with aging; 
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physiological changes that occur with normal aging often interact with pathological processes that 
underlie neurodegenerative mechanisms. Therefore, employing aged animals for the investigation 
of potential therapeutics is an important element of the clinical relevance of experiments. Finally, 
chapter 4 explores the role of astaxanthin in modulating the cognitive function and synaptic 
plasticity in healthy young and aged mice.    
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Chapter 2 
Astaxanthin attenuates neurotoxicity in a mouse model of 
Parkinson’s disease 
 
NOTE TO READERS: Portions of this chapter of been previously published in the journal of Functional 
Foods in Health and Disease (Functional Foods in Health and Disease 2017; 7(8): 562-576) and are reproduced 
with kind permission from the Functional Foods Science.  
 
 
Introduction 
Parkinson’s disease (PD) is the second most common neurodegenerative disorder. PD is 
anatomically defined by the loss of dopaminergic innervation to the striatum, leading to the 
characteristic motor dysfunctions: bradykinesia, rigidity of the limbs and a shuffling gait. 
According to the Parkinson’s Disease Foundation, PD is estimated to afflict 10 million people 
worldwide, and is thereby associated with a significant economic burden. Furthermore, PD is 
projected to become more prevalent as the largest sector of the US population gets older [1]. 
Currently, the commonly prescribed medications are based on dopamine replacement strategies. 
While they effectively mitigate motor symptoms temporarily, these drugs often become less 
effective with chronic use. The current treatment options are not adequate; there are still no 
medications available to stop or delay the progression of the disease. Therefore, there is still a 
pressing need to identify compounds capable of modulating the disease process and preventing the 
development of symptoms among these patients.  
While the exact pathological mechanisms that initiate neurodegeneration in PD are still being 
investigated, it is accepted that multiple biological processes are impacted sometime during the 
course of the disease that likely interact with and perpetuate the pathogenesis. Both 
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neuroinflammation and oxidative stress are thought to be involved in neurotoxic cascades and 
contribute to cell loss. As a result, there has been significant focus on developing therapeutic 
strategies to attenuate these aberrant conditions in an attempt to alleviate some of the cellular stress 
that causes neuronal dysfunction.   
Astaxanthin (AXT) is a xanthophyll carotenoid produced primarily by the marine algae 
Heamatococcus pluvialis. AXT is currently available as a health supplement, being marketed for 
its antioxidant capacity; however, recent research indicates that AXT has multiple putative 
mechanisms of action responsible for its various health benefits [86]. This compound is being 
investigated in relation to multiple clinical conditions including cardiovascular disease, metabolic 
syndrome, and athletic performance [42, 87, 88]. Interestingly, emerging evidence suggests that 
the proposed biological activities of AXT precisely oppose the pathophysiology that underlies 
Parkinson’s disease, revealing a distinct and promising therapeutic potential in the prevention or 
delayed onset of symptoms in PD patients. 
AXT is best known for its potent antioxidant activity, reported to be much more effective than 
other similar compounds [89]. This is likely due to the numerous actions as an antioxidant, as it 
can reduce radicals by absorption, donation of electrons, and formations of adducts with the 
reactive species. The presence of hydroxylated ionone rings that cap both ends of the carbon 
backbone distinguish the molecule from other carotenoids in its class, and enables AXT 
energetically favorable spanning the phospholipid bilayer of cell membranes. This orientation and 
chemical structure effectively protects the membrane against lipid peroxidation [42].   
 Many reports indicate that AXT reduces the evidence of oxidative damage [33, 43, 90-92]. 
AXT can also stimulate the expression or the activity of endogenous antioxidant enzymes, 
including glutathione [57, 90, 93, 94]. Glutathione is expressed in low levels in the substantia 
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nigra, being one of the factors that renders the SN more susceptible to oxidative damage compared 
to adjacent brain structures [95]. It has also been shown that there is less reduced glutathione in 
the brains of PD patients, which further indicates the involvement of this molecule and the 
oxidative status of the SN to clinical presentation [96]. Elevated levels of reactive oxygen species 
in this region promote pathological modifications of α-synuclein. For example, nitrosylated α-
synuclein that readily occurs in an oxidized environment has been shown to stimulate microglial 
output of pro-inflammatory compounds and is thereby associated with neuronal dysfunction and 
degeneration [26]. AXT may lower oxidative stress by directly neutralizing radicals and also 
through the modulation of antioxidant response signaling cascades. 
AXT has also been suggested to modulate the immune response to various insults, which 
indicates that there is a potential anti-inflammatory action for this compound. Multiple 
investigators have demonstrated that AXT can reduce the expression of inflammatory mediators 
including: inducible nitric oxide synthase and nitric oxide (iNOS/NO), nuclear factor kappa-light-
chain-enhancer of activated B cells (NFB), and interleukin 6 (IL-6) [32, 43, 77, 97]. These 
secreted factors are released in high amounts by activated microglia and are associated with 
neuronal damage. A modulatory action of AXT on these microglial responses to brain insults 
represents a possible approach to interrupting one of the factors known to perpetuate neuronal 
dysfunction in the PD brain.   
Interestingly, AXT has been shown to be protective in cell culture systems against the toxic 
compounds used to produce in vitro experimental models of PD. For example, Lui et al. (2009) 
demonstrate that AXT pretreatment effectively protects SHSY5Y cells against 6-
hydroxydopamine, a commonly used toxin that degenerates the dopaminergic cells primarily as an 
oxidative insult. In this study, AXT attenuated neurotoxicity was associated with reduced ROS 
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production, in addition to DNA fragmentation, cleavage of poly (ADP-ribose) polymerase, and 
cytosolic cytochrome C [33]. AXT pretreatments have also successfully protected PC 12 cells from 
1-methyl-4-phenylpyridinium (MPP+) [34, 57, 58, 98]. MPP+ is a toxic derivative of 1-methyl-4-
phenyl-1,2,3,6-tetrahydropyridine (MPTP), another established agent used to recapitulate 
dopaminergic cell degeneration and is also widely used to model PD. In light of how AXT has 
been shown to be protective in cell culture systems against PD specific compounds, we evaluated 
the efficacy of AXT supplementation to prevent neurodegeneration in vivo at a physiological 
relevant dose.   
In the present study, we explore the capacity for a dietary pre-treatment of AXT to protect 
against neuronal damage caused by the neurotoxin MPTP. C57BL6 mice (3 months) were treated 
with AXT for one month. These mice consumed an AXT enriched diet formulated to deliver a 
dose of 3mg/kg/day (treatment group-AXT). Multiple studies have reported a range of doses of 
AXT that were used therapeutically across various disease models; this dose was chosen in order 
to determine the efficacy of the physiological levels that would occur in humans taking the 
recommended dose of commercially available dietary supplements. Additional groups were fed 
the standard grain based rodent diet (control treatment groups; CTL) or the control diet containing 
the inactive ingredients of the AXT supplement product to serve as the vehicle control condition 
(vehicle treatment group; VEH). After a month of dietary pre-treatment, half of the mice from each 
dietary condition received 4 injections of MPTP at 10 mg/kg intraperitoneal once per hour for 4 
hours to achieve a total dose of 40mg/kg. They were then allowed to recover for 7 days. In this 
study, we show that the AXT supplemented diet protected against neurodegeneration and 
inflammation which typically occurs after exposure to MPTP.  
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Table 1: A schematic over view of experimental procedures. Diagram depicts the time frame of 
dietary treatment in relation to MPTP administration. The table depicts number of animals used 
in each experimental condition.  
 
 
 
 
Groups: NaCL MPTP 40 mg/kg 
CTL 7 7 
VEH 7 8 
AXT 3 mg/kg 10 10 
 
 
Materials and methods 
All procedures were conducted according to the National Institute of Health Guide and Use 
of Laboratory Animals and the University of South Florida IACUC. Male C57BL/6J mice at 3 
months of age were maintained in environmentally controlled conditions of 21⁰ C under a 12 hour 
light/dark cycle. The mice were allowed ad libitum access to food and water. However, the food 
was consistently monitored and replaced daily by research staff to maintain freshness.  
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Dietary pretreatment: Mice were treated with 3 mg/kg of Bioastin® generously supplied by 
Cyanotech. This is a natural astaxanthin product delivered on inert cellulose beads with trace 
amounts of vitamin E.  For this reason, we included a separate group treated with the empty beads 
to serve as a vehicle control. These compounds were incorporated into the Harlan Teklad rodent 
diet, and delivered ad libitum for 1 month prior to MPTP administration. Food intake per cage and 
individual body weights were monitored throughout the course of treatment to ensure 
consumption.    
MPTP administration:  The MPTP-HCL (Sigma-Aldrich) was diluted in sterile saline and injected 
intraperitoneally. The mice received four injections at a dose of 10 mg/kg, administered once per 
hour for four hours for a final dose of 40 mg/kg MPTP, or equal volumes of sterile saline for 
control conditions. Mice were allowed to recover from MPTP exposure for 7 days before they 
were fully anesthetized with phenobarbital and transcardially perfused with phosphate buffered 
saline. Brains were immediately removed and one hemisphere was microdissected for areas of 
interest. The other hemisphere was preserved in 4% paraformaldehyde for 24 hours. The brains 
were then transferred to a 30% sucrose solution for cryoprotection.  
Immunohistochemistry: 40 m coronal sections were selected at a periodicity of 1 in 6 for all 
immunohistochemical procedures; additional sections were included both anterior and posterior to 
the SN to ensure thorough representation of the area of interest. Free floating sections were 
incubated in primary antibody (TH: Immunostar 1:1,000, IBA1: Wako Laboratory Chemicals 
1:2,500, NeuN: Millipore 1:5,000) diluted in goat serum and TX-100 for 24 hours at 4⁰ C and 
secondary antibody for 60 minutes at 25⁰ . After incubation in avidin-biotin complex (Vector 
Labs), precipitation reactions were developed with diaminobenzidine (Sigma-Aldrich).     
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Quantification: Immunoreactivity was quantified using an AxioScan microscope (20X objective) 
and NearCYTE image analysis software (nearcyte.org). This program applies a user defined 
threshold of color intensity to images of the sections and generates a ratio of positive staining 
within a region of interest. Our lab has previously determined that data collected with the 
NearCYTE software accurately reflects stereological cell counts [99].  
Glutathione assay: Briefly, plasma samples isolated from whole blood collected directly from the 
heart before transcardial perfusion. Samples were immediately diluted 1:20 in a 5% solution of 
sulfosalicylic acid for deproteination and preservation. All subsequent steps in this assay was 
performed according to manufacturer’s instructions (Arbor Assays).  
GDNF ELISA: Briefly, snap frozen samples of striatum were quickly homogenized and 
centrifuged to collect lysates. Protein concentration was determined and 40 ug of sample was 
loaded into the wells while the rest of the assay was conducted according to manufacturer’s 
instructions (BOSTERbio).  
Data Analysis:  The data presented graphically as the group mean and standard error of the mean. 
Statistical analysis was performed using GraphPad Prism software. 2 Way ANOVAs were 
conducted, while Bonferroni multiple comparisons posthoc tests (unless otherwise specified) were 
used to further compare differences between groups. 
 
Results 
AXT prevents MPTP induced neurodegeneration  
As expected, we observed approximately 50% loss of tyrosine hydroxylase positive 
staining in the substantia nigra of mice fed the control diet one week after MPTP administration. 
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Mice that were fed a vehicle control diet demonstrated a similar TH loss as the controls. However, 
the AXT enriched diet was able to preserve the TH expression in this region (Figure 1).  
 
 
 
Figure 2.1: One month dietary supplementation with AXT preserves TH immunoreactivity in the 
substantia nigra pars compacta in response to MPTP. A) Bar graph of percent area of positive 
staining of TH relative to a user defined threshold. B) Immunohistochemistry with anti-TH 
antibody in the SN. 2-way ANOVA; diet effect: DF 2, F 4.458; Bonferroni posthoc p<0.05; Scale 
= 100 m 
 
Likewise, we also observed reduced positive staining for tyrosine hydroxylase in the striatum 
of mice that were fed the control and vehicle diets. However, mice that consumed a diet enriched 
with AXT were protected from this loss of TH immunoreactivity, indicating less destruction of the 
terminals that innervate the basal ganglia (Figure 2).  
It is known that MPTP treatment can directly reduce the levels and efficacy of the TH enzyme, 
and this deficit may be transient. Therefore, an additional immunohistochemical assessment was 
conducted to assess the surviving neurons in the SN. The digital image quantification of neuronal 
nuclei (NeuN) staining revealed that the AXT enriched diet reduced neuron loss 7 days after MPTP 
exposure in the SN compared to the other diets, corroborating the trends observed in TH retention 
(Figure 3).  
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Figure 2.2: One month dietary supplementation with AXT reduces TH immunoreactivity loss in 
the striatum in response to MPTP.  A) Bar graph of percent area of positive staining of TH relative to a 
user defined threshold. B) Immunohistochemistry with anti-TH antibody in the striatum. 2 way ANOVA, 
Diet effect DF 2, F 14.08 Newman-Keuls *p<0.05 **p<0.001; Scale = 200 m 
 
 
Figure 2.3: One month dietary supplementation with AXT preserves neurons in the SN in response 
to MPTP. A) Bar graph of percent area of positive staining of NeuN relative to a user defined threshold. 
B) Immunohistochemistry with anti-NeuN antibody in the SN. 2-way ANOVA, Diet effect DF 2, F 4.2. 
Tukey multiple comparison p<0.05; Scale = 200 m 
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AXT alters microglial response to MPTP neurotoxicity 
It has been postulated that AXT may modulate microglial function and their reactivity to 
various insults [32, 51, 100]. Microglial express ionized calcium-binding adaptor molecule protein 
1 (IBA1) at basal levels, but are known to upregulate this molecule when exposed to certain 
immune stimuli; the induction of IBA1 typically indicates microglial activation. Therefore, we 
examined the expression of IBA1 in the striatum and SN. In this study, we demonstrate that MPTP 
leads to an increase of IBA1 in the striatum in the control fed mice and approaches significance in 
VEH treated mice. In contrast, AXT supplementation minimized the increase in expression of 
IBA1 (Figure 4). Interestingly, we did not observe a significant increase in IBA1 in the SN of 
control fed MPTP treated animals but we observed that AXT treatment reduced basal levels of 
microglial expression of IBA1 in the SN compared to control mice (Figure 5). This lower basal 
level of IBA1 was maintained in the MPTP treated group with AXT treatment (Figure 5).  
 
 
 
Figure 2.4: Dietary intervention of AXT modulates microglial response to the neurodegeneration 
that results from MPTP neurotoxicity. A) Bar graph of percent area with positive staining of IBA1 
in the striatum relative to a user defined threshold. MPTP induced upregulation of the microglial 
marker IBA1 is attenuated in the striatum of mice being treated with AXT 2-way ANOVA, Diet 
effect DF 2, 3.3 F; Tukey’s multiple comparison (*p< 0.05); B) Immunohistochemistry with anti-
IBA1 antibody in the striatum. Scale = 20 m 
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Figure 2.5:  Dietary intervention of AXT modulates microglial response in the SN. A) Bar graph 
of percent area with positive staining of IBA1 relative to a user defined threshold. IBA1 in the SN 
is reduced with AXT treatment. 1 way ANOVA of saline treatment with Bonferroni multiple 
comparison (*p < 0.05); B) Immunohistochemistry with anti-IBA1 antibody in the SN. Scale = 
20m 
 
Antioxidant effect  
Oxidative stress is considered to be involved in both the pathogenesis of PD and to 
contribute to the neurotoxicity of MPTP [101]. Many therapeutic strategies aim to mitigate the 
damage caused by excessive release of reactive oxygen species. It has been suggested that AXT 
can increase the efficacy of endogenous antioxidant enzymes, either by increasing their expression 
levels or their enzymatic activity. As previously mentioned, it is well documented that AXT has 
an antioxidant effect and can protect biological systems, including both cell culture and whole 
organisms from oxidative damage, [36, 43, 57, 58, 92]. Therefore, we assessed the levels of 
glutathione in the plasma. In our study, one month of AXT supplementation significantly elevated 
the ratio of reduced glutathione (GSH) to oxidized glutathione (GSSH). Even after exposure to 
MPTP, the AXT treated animals still retained a more favorable ratio of GSH to GSSH than the 
control mice, despite the increased output of reactive oxygen species known to occur in this model 
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(Figure 6). In contrast, mice on the standard control diet had lower levels of GSH after MPTP 
exposure.  
 
 
 
Figure 2.6: A) AXT increases the ratio of reduced glutathione (GSH) to oxidized glutathione 
(GSSG). Bar graph of the relative ratio of GSH:GSSH in plasma. AXT increases the ratio in both MPTP 
treated and non-MPTP animals compared to control animals. 2-way ANOVA Diet effect: DF 1, F 14.51; 
Bonferroni multiple comparisons (*p<0.05). B) MPTP exposure is associated with increased expression of 
GDNF in the striatum. AXT treatment suppresses the elevation of GDNF in response to MPTP. 2 way 
ANOVA Diet effect: DF 1, F 3.8: Bonferroni multiple comparisons (*p<0.05) and independent T-tests. 
 
AXT modulates growth factor expression in the striatum 
It has been shown that AXT can stimulate the expression of brain derived neurotrophic 
factors in various brain regions in vivo. We evaluated another growth factor, GDNF, because of 
its expression in the striatum and relevance to Parkinson’s disease. GDNF is necessary for the 
postnatal development of dopaminergic cells within the midbrain and stimulates neurite 
outgrowth, facilitating integration and connectivity of the new cells. Incubating fetal grafts in 
GDNF also aids in the survival of transplantation into the ventral midbrain [102, 103]. GDNF has 
been evaluated for its therapeutic potential for supporting fiber growth and re-innervation of the 
striatum during the progressive cell loss in PD. Several preclinical animal studies have 
demonstrated that enhancing GDNF expression within the striatum can offer protection against 
toxic injury. For example, the viral vector driven expression of GDNF in the striatum of the 
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common marmoset was found to be protective against the degeneration of dopaminergic terminals 
caused by 6-hydroxydopamine injections. This neuroprotection was observed with GDNF levels 
moderately above physiological levels and was associated with improved behavioral outcomes 
compared to the lesioned animals [104]. In this study, we show how MPTP treated mice on either 
the control or vehicle control diets have higher levels of GDNF in the striatum compared to the 
saline injected animals (Figure 6). In contrast, we did not observe this increase in the mice that 
consumed the AXT enriched diet. Furthermore, AXT treatment alone seemed to elevate the 
expression of GDNF in the striatum compared to the control diet in the saline injected mice.  
 
Discussion 
While PD is common among the elderly, there are no available medications to cure, prevent, 
or delay the progression of the disease. Levidopa and other routinely prescribed medications are 
only palliative; they are effective at restoring dopamine. However, this only addresses motor 
symptoms and does not prevent ongoing neurodegeneration. Therefore, elucidating disease 
modifying agents and developing strategies to delay or prevent the onset of symptoms are critical 
for the treatment of PD. AXT is a possible disease modifying agent that can interrupt various 
mechanisms involved in the toxic cascade of MPTP. This is noteworthy because neurotoxic 
mechanisms of MPTP, such as oxidative damage, mitochondrial dysfunction (complex 1 
impairment), and neuroinflammation are also known to be involved in the pathogenesis of PD. 
Other studies have supported the therapeutic strategy of using natural compounds in the treatment 
of disorders with similar pathological elements of inflammation and oxidative stress [105]. 
Mitigating multiple pathological mechanisms is a clear advantage of an AXT based therapeutic 
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strategy. Furthermore, this compound can be considered for use chronically as a preventative or 
adjuvant therapy, as there are little to no adverse effects reported to date.  
AXT is known to cross the blood brain barrier and accumulate within the brain tissue in 
addition to other organs [31]. Multiple studies have shown that AXT may also be beneficial 
specifically within the central nervous system for a variety of neurological injuries and disorders. 
For example, AXT supplementation has been purposed to augment cognitive function and 
neuroplasticity, something which has been recently reviewed [35]. AXT was protective in a mouse 
model of traumatic brain injury [39]. Ji et al (2017) demonstrated that oral AXT treatment 
prevented the loss of cortical neurons and the associated behavioral impairments usually detectable 
in mice after traumatic brain injury. Similarly, AXT administration was also able to reduce the 
damage in a model of subarachnoid hemorrhage; AXT decreased edema, blood brain barrier 
dysfunction, and oxidative damage which ultimately contributed to neuronal loss observed in the 
control animals [36]. These recent in vivo reports support the therapeutic potential of AXT for 
neurological based diseases. 
In the present study, we used astaxanthin, a naturally derived carotenoid, to mitigate 
neurotoxicity using an MPTP mouse model of Parkinson’s disease. Our data suggests that the 
mechanisms underlying AXT mediated neuroprotection are related to modulating inflammation 
and oxidative stress. We determined that AXT supplementation effectively protects against the 
loss of dopaminergic neurons in the substantia nigra and their TH enriched terminals in the 
striatum. We also show that dietary AXT administration altered the microglial response to MPTP 
induced neurodegeneration, as IBA1 induction was not observed in the AXT treated animals. 
These results are consistent with previous work showing how AXT in cell culture can attenuate 
the toxicity of 6-hydroxydopamine and MPP+ [33, 57, 58, 98]. It also corroborates many 
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preliminary studies that demonstrate AXT treatment may modulate the output of inflammatory 
cytokines.  For example, AXT has been shown to reduce transcripts of proinflammatory mediators 
[77]. Functionally, the administration of AXT can block some inflammatory sequelae of the 
immunogen lipopolysaccharide injections [100] and can inhibit NFB translocation to the nucleus, 
thereby down-regulating TNF- expression [106]. Treatments that reduce microglial activation 
such as fractalkine [107] or the Rho Kinase inhibitor Fasudil [108] are known to reduce the 
neurotoxicity of MPTP. Therefore, it is likely that the effect of AXT to reduce IBA-1 is directly 
related to the neuroprotection observed in this study. 
We also show that AXT intake was associated with a more favorable ratio of GSH reduced 
glutathione to GSSH, oxidized glutathione in the plasma. Reduced glutathione indicates less 
oxidative stress, possibly either from increased levels or increased efficiency of glutathione to 
neutralize free radicals in the cellular environment. As discussed previously, glutathione status is 
of interest in Parkinson’s disease, as the levels of this endogenous antioxidant molecule are 
substantially decreased within the PD brain and are thought to perpetuate oxidative damage that 
contributes to neuronal atrophy. Interestingly, pharmacological reduction of glutathione in vitro 
has been directly linked to nitrosylation of mitochondrial proteins leading to complex 1 deficiency. 
Mitochondrial dysfunction is another pathological characteristic of the PD brain [109]. 
Furthermore, measuring glutathione in the plasma correlates with the severity of cognitive 
dysfunction in Alzheimer’s disease patients [110] confirming that there is a relationship between 
peripheral GSH levels and brain function.  
The AXT modulation of glutathione observed in this experiment is consistent with other 
studies. Mattei et al. (2011) also demonstrated that AXT administration leads to improved 
antioxidant capacity including an increased ratio of GSH:GSSH in the plasma [111]. AXT was 
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shown to increase GSH levels in the liver of animals exposed to the chemical carcinogen carbon 
tetrachloride (CCl4). Kang et al. (2001) attributed the attenuation of CCL4 induced liver toxicity to 
the AXT stimulation of the endogenous antioxidant system [112]. Likewise, AXT has also been 
shown to reduce excitotoxicity in an animal model of epilepsy. These authors demonstrate that 
AXT treatment reduced neuronal apoptosis and upstream oxidative damage induced by 
overstimulation of the amygdala. This protective effect was associated with an increase in 
glutathione and a decreased output of reactive oxygen species [92]. While oxidative stress plays a 
role in the pathogenesis of Parkinson’s disease, it is not the only major biological process 
negatively impacted during the course of disorder. It is notable that many antioxidant compounds 
have failed in clinical trials. While the antioxidant capacity of AXT likely reduces some neuronal 
dysfunction due to minimizing rampant oxidative damage, other suggested mechanisms of action 
likely come together and work in a synergistic or cumulative way to reduce the neurodegeneration 
seen in this model.  
Finally, we observed an AXT mediated effect on GDNF expression in the striatum. As 
previously mentioned, GDNF has been investigated as a therapeutic target in the treatment of 
Parkinson’s disease. Preclinical animal work supports the efficacy of GDNF based therapies as 
this growth factor has been shown to both be necessary for post-natal dopaminergic cell 
differentiation and survival in the mesencephalon, in addition to enhancing the successful 
integration of fetal tissue transplanted into the ventral midbrain [102, 103]. Additionally, 
upregulating GDNF expression above physiological levels using adeno associated viral vector 
effectively protected against degeneration caused by the 6-hydroxydopamine toxin and prevented 
the subsequent behavioral impairments [104]. It is known that growth factor expression can by 
stimulated by neuronal injury in effort to restore the damaged site [113]. We speculate that the 
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increase of GDNF that we observed after MPTP exposure in our experiment was a compensatory 
mechanism in response to the lesion formed after the toxic insult. Likewise, it is also possible that 
even a subtle increase in striatal GDNF in the mice supplemented with AXT was sufficient to 
reduce some of the cell death caused by MPTP in the first place.  
 
Conclusions 
In conclusion, we have demonstrated an effect of AXT to reduce neurodegeneration in the 
MPTP model of PD. We show a concomitant decrease in the factors of inflammation and oxidative 
stress, suggesting these processes are associated and likely mediate the protective effect of AXT 
against MPTP. MPTP is a potent neurotoxin, and one caveat of this model is its rapid time course 
and dramatic dopaminergic cell loss does not recapitulate the slow progression of pathology seen 
in PD patients. Accordingly, future studies that use AXT in additional models of PD, like the viral 
vector mediated over expression of synuclein, will establish a role in disease progression as well 
as prevention. 
Abbreviations: AXT, astaxanthin; MPP+, 1-methyl-4-phenylpyridinium; MPTP, 1-methyl-4-
phenyl-1,2,3,6-tetrahydropyridine; SN substantia nigra; STR, striatum; iNOS/NO, inducible nitric 
oxide synthase and nitric oxide; NFҡB, nuclear factor kappa-light-chain-enhancer of activated B 
cells; IL-6, interleukin 6; TH tyrosine hydroxylase; NeuN, neuronal nuclei; IBA1, ionized calcium-
binding adaptor molecule protein 1; GSH, reduced glutathione; GSSH, oxidized glutathione; 
GDNF glial derived neurotrophic factor; CCl4,carcinogen carbon tetrachloride 
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Chapter 3 
Astaxanthin attenuates neurotoxicity in an aged mouse model of 
Parkinson’s disease 
Introduction 
Parkinson’s disease (PD) is a common neurodegenerative disorder that is primarily 
characterized by motor impairments including postural instability and bradykinesia. These motor 
symptoms are caused by loss of dopaminergic neurons in the substantia nigra pars compacta 
(SNpc) resulting in degeneration of those projections to the striatum. However, there is also 
notable dysfunction in other neurotransmitter systems and brain regions that account for a cluster 
of non-motor symptoms as well. Like other neurodegenerative conditions, PD is associated with 
aging. While there are some cases that arise from a crippling genetic predisposition, only 5% of 
diagnosis are genetically linked the rest are idiopathic and have no known cause. Therefore, aging 
is considered to be the most substantial risk factor for developing PD, evidenced by the 
considerable increase in prevalence for every decade after 60. Moreover, it is projected that by 
2050, the US population over the age of 65 will double [114]. Therefore, the prevalence of this 
disorder is predicted to increase dramatically, as well as the associated economic burden of long 
term health care. Currently, the treatment of PD is largely based on enhancing the endogenous 
dopamine transmission to the striatum pharmacologically, which will successfully attenuate motor 
dysfunction temporarily but cannot prevent the neurodegenerative cascades that underlie the 
disease in the first place. However, as the disease progresses, the neural circuitry adapts to 
fluctuating levels of dopamine and the medications become less effective [115]. Furthermore, the 
commonly prescribed medications do nothing to address the non-motor symptoms that also 
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substantially impact the quality of life of the patients. The current standard of treatment is 
inadequate and it is essential to develop novel therapeutic agents that slow or prevent neuron loss.  
Interestingly, the substantia nigra has unique physiological characteristics that distinguish 
this region from similar dopaminergic centers and render this structure vulnerable to generic brain 
wide insults [7, 40]. This is largely due to high inflammation and oxidative stress. For example, 
the SN has a high population of microglia [23], which likely renders this region highly susceptible 
to inflammatory events which would have a heightened impact on the neurons of this region. 
Additionally, the SN produces unusually high levels of ROS and has low levels of glutathione, 
both of which contribute to oxidative damage and therefore cellular stress in this region [95, 96].  
The pathophysiology of PD is critically important to consider within the context of aging. 
The normal aging process inevitably leads to physiological changes, some of which interact with 
and exacerbates the pathological mechanisms that underlie the neurodegeneration. For example, 
proteostaisis and autophagy, mitochondrial function, production and resolution of reactive oxygen 
species are all biological process that lose efficacy during normal aging that are also proposed to 
contribute to cell death in PD [6]. During normal aging in humans there is a steady loss of cells in 
the SNpc at rate of approximately 7% per decade [116]. Interestingly, there are many biochemical 
similarities that lead to loss of function in this region between normal aging and Parkinson’s 
disease. For example, in both cases there is a selective vulnerability of the ventral tier of the SNpc, 
where dopaminergic cells are most impacted. Analysis of the aged non-human primate brain 
reveals that there is a marked loss of tyrosine hydroxylase (TH) within the ventral midbrain. The 
pattern of TH loss also reflects the vulnerability of subregions of dopaminergic neurons, where the 
age related decrease in TH intensity is most pronounced in the ventral tier of the SNpc. There is 
simultaneously a marked accumulation of α-synuclein within the soma of the remaining cells that 
correlates with TH loss. It has been postulated that aging leads to a pre-parkinsonian state [49, 
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116]. Neuroinflammation also increases with age and is an integral aspect of the disease process. 
One relevant age related change that contributes to increased neuroinflammation is the priming of 
microglia, where these cells become hyperresponsive to stimulation and remain activated for 
longer durations as they simultaneously become less resistant to endogenous regulatory signaling 
[15, 16]. This altered microglial response increases and prolongs the parenchyma to cytotoxic 
cytokines and reactive oxygen species (ROS).  
While there is no cure for PD, patients are often treated with medications to modulate the 
release of dopamine within the nigrostriatal circuit. These dopamine replacement drugs are 
successful at managing the motor dysfunctions, but there is no treatment in place that can prevent 
the progression of the disease. Developing drugs that can stop or reverse the neurodegeneration is 
regarded as the most important goal of the field. Despite the motives to develop more effective 
medications, clinical trials assessing novel therapeutics have been overwhelmingly unsuccessful. 
There are multiple factors that contribute to this failure rate [117] although it is possible that some 
compounds such as N-acetylcysteine and co enzyme Q10, both of which did not surpass Phase II, 
only address single biological mechanisms that are affected in PD; we know that the 
neurodegenerative cascades that lead to cell death involve multiple biological processes. Perhaps 
when screening for potential compounds in the future, we should focus on targeting multiple levels 
of pathology in order to confer a therapeutic effect and test them in the aged environment.   
Astaxanthin is a carotenoid that is produced by photosynthetic microorganisms. It is 
approved by the Food and Drug Administration as an antioxidant, and marketed as a health 
supplement. This compound has recently gained a lot of interest for its variety of health promoting 
effects [42, 86, 91]. It is being investigated as a treatment for a variety of clinical conditions, 
generating data from diverse model organisms that collectively suggest that this compound has 
multiple mechanisms of action [86]. Interestingly, these proposed mechanisms of action seem to 
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counteract the pathological mechanisms that contribute to cell loss in PD. For example, AXT has 
been suggested to modulate immune function including microglial activation [32, 44, 51, 88, 106], 
enhance mitochondrial function [33, 34, 43] and is known to be an effective antioxidant [36, 46, 
47, 98]. We have previously shown that AXT supplementation is neuroprotective against MPTP 
in young animals [118]. Pharmacokinetics confirm that AXT can cross the blood brain barrier, as 
its chemical properties of hydrophobicity would suggest. AXT will associate with lipid dense 
cellular membranes and predominantly accumulate in the liver, although it is known to also 
accumulate in the brain [31]. Recent reports support that AXT can exert its activity within the CNS 
and demonstrate neuroprotective mechanisms against multiple neuronal insults. For example, 
AXT has been suggested to enhance neuroplasticity and cognitive function [35]. Additionally, 
AXT supplementation was shown to be protective against traumatic brain injury, preserving 
cortical neurons and reducing the subsequent behavioral deficits [39]. Likewise, AXT treatment 
also protected against neuron loss in a model of subarachnoid hemorrhage [36]. Recent 
experimentation further supports the efficacy of AXT in vivo, lending support to the concept of 
AXT based therapeutic strategies in neurological conditions.  
In chapter 2, we demonstrate that AXT supplementation can reduce the neurotoxicity of 
MPTP in mice 3 months of age. However, it is important to note that many compounds that have 
been successful pre-clinically have largely failed in clinical trials and a need for novel agents that 
can halt the neurodegenerative process remains unmet. Given that aging is in fact the biggest 
predictor of developing PD, the field has started to focus on the value of aged experimental animal 
models, with the thought that the physiology in aged animals is a more relevant backdrop to the 
human condition, thus possibly lending to more predictive validity [119]. Therefore, here we 
investigate the efficacy of AXT supplementation against MPTP neurotoxicity in aged animals. 
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Materials and Methods 
All procedures were conducted according to the National Institute of Health Guide and Use 
of Laboratory Animals and the University of South Florida IACUC. Male C57BL/6J were used in 
these studies at both 3 and 18 months of age. Animals were housed in groups of 4 and maintained 
in controlled conditions of 21⁰C and a 12 hr light/dark cycle. The rodent diets were fed daily by 
an experimenter in order to ensure freshness of the food and added test compounds, while the 
animals fed ad libitum. In order to confirm that the mice were consuming the enriched diets, 
research staff regularly recorded the food intake and body weight of the mice and did not observe 
any significant differences in weight gain over the course of the experiment due to the dietary 
treatments. 
Dietary pretreatment: Mice were treated with Bioastin® generously supplied by 
Cyanotech to achieve a dose of 30 mg/kg bodyweight. Bioastin® is a product designed to deliver 
algal derived, natural astaxanthin on a microbead comprised of mostly inert ingredients like 
cellulose and gelatin. However, this product does have trace amounts of other compounds 
including vitamin E and these microbeads comprise a high volume of the total Bioastin® product. 
We have previously shown that the vehicle condition does not have an effect, and we saw similar 
results in this study, therefore, we do not present the data again here in this report. These 
compounds were incorporated into the standard Harlan Teklad rodent diet, and delivered ad 
libitum for 1 month prior to MPTP administration. Food intake per cage and individual body 
weights were monitored throughout the course of treatment to ensure consumption.    
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Table 2: A schematic over view of experimental procedures. Diagram depicts the time frame of 
dietary treatment in relation to MPTP administration. The table depicts number of animals used 
in each experimental condition.  
 
 
Groups: 
 
NaCL MPTP 40 mg/kg 
Young CTL 7 7 
Young AXT 
30 mg/kg 
11 10 
Aged CTL 7 6 
Aged AXT 
30 mg/kg 
10 10 
  
 
MPTP administration:  The MPTP HCL (Sigma-Aldrich) was diluted in sterile saline and injected 
intraperitoneally. The mice received four injections at a dose of 10 mg/kg, administered once per 
hour for four hours for a final dose of 40 mg/kg MPTP. Because aged mice may be more 
susceptible to MPTP toxicity, this dose was pilot tested in a separate aged cohort to ensure that it 
would not cause excessive mortality. Mice in the control condition received equal volumes of 
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sterile saline delivered in the same time course. Mice were allowed to recover from MPTP 
exposure for 7 days before they were fully anesthetized with phenobarbital and transcardially 
perfused with PBS. Brains were immediately removed and one hemisphere was microdissected 
for the structures of interest. The other hemisphere was preserved in 4% paraformaldehyde for 24 
hours. The brains were then transferred to a 30% sucrose solution for cryoprotection.  
Immunohistochemistry: Paraformaldehyde fixed brains were treated with a 30% sucrose solution 
for three days to ensure cryoprotection before 40 m thick slices were prepared using a cryostat. 
Every 6th section was selected for consistent sampling for IHC procedures, including extra sections 
outside of the regions of interest to ensure thorough sampling and analysis.  Free floating sections 
were blocked in goat serum before being incubated in primary antibody (TH: Immunostar 1:1,000, 
IBA1: Wako Laboratory Chemicals 1:2,500, NeuN: Millipore 1:5,000). Primary antibodies were 
diluted in PBS containing goat serum and Triton X-100 overnight at 4oC while the sections were 
incubated in secondary antibody for 60 minutes at 25oC. Avidin-biotin complex (Vector Labs) was 
used to increase substrate formation from the precipitation reactions were developed with 
diaminobenzidine (Sigma-Aldrich).     
Quantification: Estimated population of IBA 1 and TH positive cells was determined using the 
optical fractionator probe and unbiased stereological methods from Microbrightfield, (Cholchester 
VT). Substantia nigra was sampled with a counting frame of 150x150 and grid size of 200x200 
µm, while the striatum sampled with the same size counting frame and a grid size of 300x300 µm. 
IHC data presented as a percent positive area was quantified using a digital image analysis 
program, NearCYTE (nearcyte.org), previously described [99]. Briefly, high resolution images 
were created with the AxioScan microscope at a 20x objective. Using NearCYTE software, regions 
of interest were traced over the digital slide images, then compared to a standard of intensity 
dictated by an experimenter blind to treatment conditions. This comparison essentially generates 
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a ratio of the number of pixels that match this user defined criteria within the region compared to 
those that fall below the threshold. It is necessary to evaluate the immunoreactivity of TH in the 
striatum in this manner, as this region consists of cross sections of dopaminergic terminals yielding 
a diffuse staining pattern. However, we have previously determined that data collected with 
NearCYTE and expressed as a percent positive area also reliably and accurately corroborates the 
data collected with unbiased stereology and presented as an estimated population of positive cells 
within a region. [99].  
High-Performance Liquid Chromatography: In order to verify that the experimental conditions 
did not differentially affect AXT absorption, we evaluated the levels of AXT in the plasma by 
HPLC using a liquid-liquid extraction method.  Briefly, 100 μL of plasma was spiked with 100 μL 
acetone containing 1 μg/mL of testosterone as an internal standard and vortexed for 5 minutes at 
room temperature. 200 μL of N-hexane was added, vortexed again for 5 min at room temperature, 
then centrifuged at 14000 rpm at 25 oC. The upper organic layer was transferred to a 96 well plate 
and dried under gentle nitrogen stream. The dried extract was reconstituted with 100 μL of MeOH.  
100 L of the resulting extract was injected on a Thermo HPLC system equipped with PAL 
CTC plate sampler (96-well plate), Dionex Ultimate 3000 binary pump (flow rate at 1 mL/ min), 
Dionex Ultimate 3000 thermostatted column compartment (temperature at 40oC), Thermo Endura 
Mass Spectrometer (ESI source), using Phenomenex Develosil® (3 μm, 4.6 x 50 mm, 140Å) 
column under isocratic condition of MeOH aq (0.1% formic acid) starting at 98% during 0.5 min, 
then under gradient condition of 98 - 100% MeOH aq (0.1% formic acid) over 4 min, finishing at 
100% of MeOHaq (0.05% formic acid) over 0.5 min then returning to 98% MeOH aq for another  
1 min to re-equilibrate. For quantification, trans-astaxanthin was diluted in DMSO then spiked into 
plasma to generate calibration curve. 
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Plasma levels of AXT were determined by calculating the area of the peak relative to the 
AXT calibration curve. AXT level was adjusted to the internal standard concentration to correct 
for analyte lost during the extraction process.  Peak height measurements were conducted referring 
to values obtained for standards of known concentrations. 
Data Analysis:  The data presented graphically as the group mean and standard error of the mean. 
Statistical analysis was performed using GraphPad Prism software. 2 Way ANOVAs were 
conducted, while Bonferroni multiple comparisons posthoc tests (unless otherwise specified) were 
used to further compare differences between groups. 
Results 
AXT rescues MPTP induced neurodegeneration 
 We have previously shown that a diet enriched with AXT can attenuate MPTP induced 
neurotoxicity [118]. Here, we corroborate our previous experiments and show that AXT 
supplementation can preserve the population of TH containing neurons in the substantia nigra pars 
compacta in young animals. As expected, we observed a significant reduction in TH positive 
neurons in the SNpc of MPTP injected mice that consumed the standard NIH rodent diet (CTL) 
compared to their saline injected counterparts. In contrast, the animals that were fed the AXT diet 
were protected from this loss of TH immunoreactivity (Figure 1 A, B). In the aged animals, we 
observed a similar impact of MPTP toxicity as compared to the young. However, we did not detect 
a protective effect of AXT on TH levels in the SNpc in the aged animals (Figure 1 C, D). This 
disparity does not seem to be due to an age related interruption in the absorption of dietary AXT 
(Table 1). In fact, according to HPLC analysis, both young and aged animals have similar levels 
of AXT in the plasma, suggesting that this dose of AXT has reduced efficacy in the aged animals, 
at least with respect to recovery of TH immunoreactivity.  
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Table 3: Concentrations of AXT detected in the plasma by high performance liquid chromatography 
 
 
 
Astaxanthin concentration in the plasma (ng/mL) 
Group Average Standard Dev. N 
Young NaCl 47 6.7 6 
Young MPTP 61 11.3 9 
Aged NaCl 40 4.1 7 
Aged MPTP 41 4.5 11 
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Figure 3.1: Consumption of the AXT enriched diet attenuates the loss of TH positive neurons in 
the substantia nigra pars compacta in young mice A, B) while aged animals do not demonstrate 
any protection against MPTP induced neurodegeneration C, D) compared to the saline (NaCl) 
control injection. A) Bar graph of stereological quantification of TH positive neurons in the SNpc 
in young and C) aged mice. Data is represented as mean + SEM. Immunohistochemistry with anti-
TH antibody in the SNpc of B) young and D) aged mice. 2 way ANOVA; Young: p<0.05: Diet 
effect: p<0.01 DF: 1, 19 F:8.65; Bonferroni post hoc: *p<0.1; 2 tailed T test: **p<0.01 Aged: not 
significant; DF: 1, 11 F: 1.03; Bonferroni post hoc: ** p<0.01: 2 tailed T tests: **p<0.01 
***p<0.001. Scale = 200 m 
  Consistent with previous reports, we show a similar effect of striatal TH preservation in 
young animals that were pretreated with the AXT enriched diet (Figure 2 A, B). As expected, we 
measure a significant reduction in TH immunoreactivity after MPTP injections in animals that 
were fed the CTL diet. Animals that were fed a diet supplemented with AXT retained more TH 
immunoreactivity after MPTP exposure compared to controls. However, AXT supplementation 
did not effectively rescue the TH immunoreactivity in the aged animals, which should show similar 
levels to the MPTP CTL diet group (Figure 2 C, D).  
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Figure 3.2: Consumption of the AXT enriched diet protects against the loss of TH positive fibers 
innervating the striatum in young mice. However, aged mice show similar levels of denervation 
after MPTP regardless of the diet. A bar graph of the positive area of striatal levels of TH in the 
young mice A) and aged mice C). Data is represented as mean + SEM. Immunohistochemistry 
with anti-TH antibody in the striatum of B) young and D) aged mice. 2 way ANOVA; Young: 
p<0.05, DF 1, 13 F: 6.4; Bonferroni post hoc: **p<0.01, 2 tailed T test: *p<0.05; Aged: not 
significant; DF: 1, 29 F: 0.02: Bonferroni post hoc: ***p<0.001 Scale = 200 m 
 
 MPTP is a mitochondrial toxin and leads to the excessive release of reactive nitrogen 
species. Therefore, the MPTP toxin can immediately alter the expression of the tyrosine 
hydroxylase protein through nitrative modifications, without overtly leading to dopaminergic cell 
death. In this case, without neurodegeneration, it has been observed that short term reduction of 
TH can eventually be recovered in this experimental model. We quantified neurons by staining for 
neuronal nuclei (NeuN) in order to further assess the degree of neuron loss vs TH loss. We observe 
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that the expression TH reflects the retention of NeuN in the young animals (Figure 3 A, B). As 
expected, the different dietary conditions alone do not seem to alter the number of neurons in the 
SNpc. However, exposure to the MPTP toxin reduces neurons in the SNpc of animals that were 
fed the CTL diet compared to the saline injected controls. As expected from our previous work, 
AXT supplementation protected against this MPTP induced neurodegeneration in the young 
animals (Fig 3 A, B).  Interestingly, we also observed this protective effect against neuron loss in 
the aged animals (Fig 3 C, D). While AXT supplementation did not rescue levels of TH after 
MPTP, it did attenuate the loss of NeuN in the same area, suggesting that there was still a dietary 
neuroprotective effect against widespread cell death in the SNpc of the aged animals. 
 
Figure 3.3: AXT enriched diet protects against neuron loss in the SNpc exposed MPTP. Both 
young and aged mice that were treated with AXT show a retention of neurons in the SNpc despite 
the MPTP insult.  A Bar graph of percent area of positive staining of NeuN relative to a user 
defined threshold in A) young mice and C) aged mice. Data is represented as mean +  SEM. 
Representative images of immunohistochemistry with anti-NeuN antibody in the SNpc of B) 
young and D) aged mice. 2 way ANOVA; Young p<0.05, DF: 1, 11 F: 8.26; 2 tailed T tests: 
***p<0.001; Aged: p<0.05 DF: 1, 29 F: 7.48; 2 tailed T test: *p<0.05 Scale = 200 m 
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AXT alters microglial response to MPTP neurotoxicity 
 Neuroinflammation is a major contributing factor in the neurodegenerative process that 
underlies PD. Multiple reports suggest that AXT has anti-inflammatory properties [32, 97, 98, 
120]. In the brain, the inflammatory response is predominantly carried out by microglia. Therefore, 
we investigated the microglial response to MPTP neurotoxicity across dietary conditions. 
Microglia are motile and can infiltrate areas of neuronal damage to phagocytose degenerating 
neuronal material and initiate the repair process. In a preliminary assessment of the microglial 
response, we quantified the area of IBA1 staining in the SNpc. We observed that the toxic insult 
of MPTP induces an increase of IBA 1 detected within SNpc and that the AXT diet moderately 
attenuates this response in young animals. Similarly, we also saw an MPTP induced increase of 
IBA1 staining in the SNpc of aged animals, however the AXT treatment seemed to further increase 
levels of IBA1 (data for area analysis not shown). Based on this area analysis, it is unclear if the 
changes in IBA 1 staining are due to alterations in overall microglial phenotype and morphology, 
or simply because there are more microglia in the SNpc. Therefore, we examined the number of 
microglia in the SNpc by counting the number of IBA 1 positive cells in the SNpc.  Stereological 
analysis of the young animals shows there are similar levels of IBA 1 positive cells in the nigra 
after MPTP exposure, suggesting that the MPTP lesion does not significantly impact microglial to 
migrate to the area of injury. Dietary treatment with AXT moderately decreases the number of 
microglia in the SNpc after MPTP injections compared to those on the CTL diet, however, this 
shift is not statistically significant (Figure 4 A, C). Based on these observations alone, it is still 
unclear if the AXT has this effect because it acts directly on the microglia, or because it is 
neuroprotective, and indirectly reduces the neurodegeneration that recruits microglia to the site of 
damage. However, in the aged animals we observed that the AXT treatment increases the number 
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of microglia in the SNpc after MPTP exposure (Figure 4 B, D). This data suggests that the 
mechanisms through which AXT is modulating microglial activity may be complex. In order to 
help clarify this issue, we next assessed microglial phenotype and morphology using unbiased 
stereology to count microglial cells that matched size and intensity criteria for activation. Because 
age itself induces some degree of microglial priming (discussed above), microglia in the aged 
animals are generally larger, darker and less ramified. Furthermore, microglia of the aged animals 
treated with MPTP clearly show a classic hyper-reactive response to the toxin. In contrast, the 
microglia in the young animals are characterized by smaller cell bodies, and have maintained their 
branched processes. Microglia in the young animals were generally phenotypically very different 
from those in the aged mice; they appear to have recovered more substantially from the MPTP 
insult, consistent with previous reports [121]. Because of these differences, we screened for 
activation compared to a baseline cell size and staining intensity of microglia in each age group. 
In the aged condition, cells qualified as activated if they were over 8 microns large (this was easily 
measured using the size of the cursor in the computer software, at a 20x objective), as well as 
hypertrophic (Figure 5 A, red arrows). In the young animals, cells were considered activated if the 
cell body measured 4 microns in size and black in color (Figure 5 A, black arrows). This was 
determined by matching the soma to the inner portion of the same cursor. As expected, our 
stereological estimates indicate MPTP stimulates microglial activation in the SNpc. Dietary 
treatment of AXT reduces microglia activation in young animals (Figure 5 B). However, aged 
animals exposed to MPTP show an increase in the activated phenotype in both of the dietary 
treatments; thus, AXT did not seem to attenuate microglial activation in the aged mice (Figure 5 
C).   
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Figure 3.4:  Exposure to MPTP increases the number of IBA 1 positive microglia in the SNpc of 
aged but not young mice.  A) Bar graph of the estimated population of IBA 1 positive microglia 
in the SNpc. Data is represented as mean +  SEM. 2 way ANOVA; Young: not significant: DF: 1, 
19 F: 0.58; Aged (B) not significant: DF: 1, 27 F: 0.33; 2 tailed T test: *p<0.05, **p<0.01.  
Immunohistochemistry with anti-IBA1 antibody in the SNpc of B) young and D) aged mice. Scale 
= 50 m 
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Figure 3.5: AXT supplementation decreases MPTP induced microglial activation in the SNpc of 
both young and aged mice. A bar graph of estimated population of activated microglia cells in the 
SNpc of B) young and C) Data is represented as mean + SEM. aged mice. 2 way ANOVA: Young: 
*p<0.05, DF: 1, 18 F: 7.03: 2 tailed T test: ***p<0.001; Aged: not significant, DF: 1, 26 F: 0.01; 
2 tailed T tests: *p<0.05, ***p<0.001. 
We observed similar microglial responses in the striatum. In the striatum of young animals, the 
number of microglia did not change significantly, likely because there was less neurodegeneration 
in these animals compared to their aged counterparts (Figure 6 A, B). In contrast, we detected 
substantially more microglial infiltration in the striatum of aged animals that were injected with 
MPTP and the dietary treatment of AXT did not significantly decrease the number of microglia in 
the striatum compared to the numbers observed in the CTL diet animals (Figure 6 C, D).   
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Figure 3.6: In young animals, the number of microglia in the STR was not altered by MPTP or 
the AXT treatment. However, the aged animals show a significant increase in microglial migration 
to the MPTP lesioned area that was not attenuated by the AXT supplementation. A bar graph 
illustrating the estimated population of IBA 1 positive cells in the striatum of A) young and C) 
aged mice. A) 2 way ANOVA not significant; DF: 1, 25 F: 0.59 C) 2 way ANOVA not significant, 
DF: 1,29 F: 0.02 2 tailed T test *p<0.05 **p<0.01. Data is represented as mean + SEM. 
Representative images of immunohistochemistry with IBA 1 in the striatum of B) young and D) 
aged mice. Scale = 50 m 
 
Discussion 
PD is very prevalent neurodegenerative disease and its association with aging is clearly 
defined. Current medications primarily alleviate motor symptoms, while the debilitating non motor 
symptoms continue to reduce quality of life for these patients. There are no treatments available 
that address the neurodegeneration or restore the loss of neurons in the SNpc. Therefore, 
development of more effective drugs still represents a major and unfulfilled goal of this field. 
Interestingly, there have been many compounds identified in preclinical settings that demonstrated 
 63 
 
neuroprotective properties and the prospect of being developed into useful therapeutic agents. 
However, many of these compounds have failed in clinical trials. There has been some speculation 
around this translational disappointment, and recent discussion has begun to critically evaluate the 
animal models used to test novel therapeutic agents and their utility in translation. While each 
experimental model has its own pros and cons, their value and utility are dependent on the 
experimental design and endpoints, as reviewed here [122]. However, one glaring criticism of 
experimental models is the lack of use of aged animals in many of these conditions. Aging is an 
essential element involved in Parkinson’s disease; we can clearly see this relationship in the 
exponential increase in prevalence of PD in the advanced decades [123]. Even normal healthy 
aging in the absence of pathology involves many physiological changes. These age-related changes 
are especially relevant to the onset of PD, as they are pronounced in the substantia nigra pars 
compacta, the region that degenerates in PD and is responsible for the motor impairment. For 
example, it is known that these DA cells in the nigra die off with advancing age at estimated rate 
of 10% per decade [124]. Furthermore, age related DA cell loss shows a similar substructural 
vulnerability within the SNpc that reflects the patterns of degeneration seen in patients diagnosed 
with PD. In both normal aging, and in confirmed cases of PD, there is selective cell loss in the 
ventral tier of the SNpc. Moreover, these aged DA cells also show additional markers of PD 
pathology, including accumulation of synuclein within the cytoplasm, increased levels of 3 
nitrotyrosine (indicating oxidative and nitrative stress) and activation of both astrocytes and 
microglia in the vicinity [49]. It has also been observed that some elderly individuals have Lewy 
body pathology, the extent of which positively correlated with the severity of motor impairment. 
None of these patients were diagnosed with PD, but together these observations suggest that 
normal aging creates a susceptibility and similarity to PD pathology [125]. 
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The xanthophyll carotenoid AXT has recently been implicated as a possible disease 
modifying agent in the treatment of PD. It is postulated that this compound in particular is able to 
interrupt multiple mechanisms involved in the neurodegenerative cascade that occurs in PD, 
including neuroinflammation, nitrative or oxidative stress, and features mitochondrial dysfunction 
including impaired maintenance of the membrane potential. The capacity for AXT to intervene at 
various levels that feed into neurodegeneration, for it to ameliorate multiple pathological 
mechanisms is a clear advantage of using AXT therapeutically. Furthermore, this naturally 
occurring molecule has been established as relatively safe for human consumption; there have been 
little to no reported adverse events attributed to AXT supplementation [42, 126, 127]. While the 
extent of drug interactions has not yet been fully elucidated, AXT may be considered for long term 
use, possible as a preventative or adjuvant therapy.  
Here we used naturally derived astaxanthin, to attenuate the neurodegeneration caused by 
MPTP exposure, a dopaminergic cell toxin, in both young and aged mice. Our data show that AXT 
is successful in reducing the neurotoxicity in the MPTP model of PD, but has limited efficacy in 
the aged mammalian system. As previously reported, we show that an AXT enriched diet can 
effectively protect against the loss of TH positive cells in the substantia nigra pars compacta of 
young animals that were exposed to the MPTP neurotoxin. However, when injected with MPTP, 
the aged mice treated with AXT showed similar reduction in TH positive neurons compared to the 
mice who consumed the CTL diet. Similar trends were observed in the striatum. Young mice 
treated with AXT were protected from the MPTP induced neurodegeneration of dopaminergic 
projections, while mice on the standard diet demonstrated a typical reduction in TH 
immunoreactivity in the striatum. In contrast, the aged animals were not substantially protected by 
the AXT diet; aged animals that were supplemented with AXT show only a marginal retention of 
TH in the striatum after exposure to MPTP compared to the mice on the standard, control diet. It 
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has been shown that aged animals are more susceptible to MPTP, and that the neurotoxin causes a 
more dramatic reduction of TH in the aged brain [128]. Again, this highlights the importance of 
the aging process and its interaction with the underlying pathophysiology of Parkinson’s disease. 
Our observations of less robust neuroprotective effect of AXT in the aged animals may be partly 
due to this increased vulnerability in the aged microenvironment. It is possible that AXT was not 
able to fully protect against the loss of TH from MPTP toxicity because this dose of MPTP was 
effectively stronger in the aged animals than in the young.   
It is known that MPTP can cause a temporary decrease in TH expression without overt cell 
death. For this reason, we also quantified the neuronal nuclei to determine if the loss of TH 
coincided with the loss of neurons in the SNpc. In the young animals the changes in NeuN 
expression corroborate the trends in TH, suggesting that MPTP injections caused 
neurodegeneration in the mice that were fed the normal, control diet, but AXT treatment preserved 
the neurons in the SNpc. Interestingly, we also observed a rescue of NeuN positive cells in the 
aged animals fed the AXT diet compared to the control diet. This indicates that although there is 
still a decrease in TH after MPTP in the aged animals, AXT may still offer some neuroprotective 
effect in the aged mice. Often loss of TH is transient and it is possible that the aged DA neurons 
had not yet fully restored the TH content at 7 days following MPTP. It is possible that if we allowed 
animals to recover from MPTP toxicity for a longer period of time, we may have observed a dietary 
treatment effect in TH levels as well.  It is also possible that a higher dose of AXT is needed in the 
aged mice, as there are differences in how the aged mice respond to MPTP as discussed above.  
However, it is our belief that the AXT mediated retention of neuronal nuclei is indicative of 
surviving DA cells in the nigra, thus leaving the potential for significant recovery of DA 
transmission.   
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We also report that AXT supplementation can influence the microglial response to MPTP 
induced neurotoxicity, as the patterns of IBA1 staining were altered across dietary treatments. Data 
from the current study corroborates preliminary studies indicating that AXT may modulate the 
inflammatory reaction to various CNS insults. For example, Yook et al, 2016, observed reduced 
transcription of proinflammatory mediators in mice treated with AXT [77]. Other studies 
corroborate this shift of transcription of inflammatory cytokines, and show that AXT can also 
suppress TNF- expression by blocking the translocation of NFB to the nucleus [106]. It has also 
been shown that animals treated with AXT have a reduced inflammatory response to LPS 
administration, and are protected from the damage that occurs from the inflammatory sequelae of 
this robust inflammogen [100]. These observations are noteworthy because, while the 
pathophysiology that underlies neurodegeneration in PD is complex, modulating microglial 
activity has been clearly shown to be a successful and viable therapeutic strategy. For example, it 
is known that compounds including fractalkine [107] or the Rho Kinase inhibitor Fasudil [108] 
that can directly act on microglia and modulate their response have been effective in preclinical 
studies at mitigating the neurodegeneration in an MPTP model. This suggests to us that the trends 
we observed in IBA-1 staining are directly related to the neuroprotective effect of AXT in the 
young animals.  
However, the aged animals show a different microglial response to the AXT. This may be 
due to a number of factors as the normal aging process includes a number of physiological changes, 
many of which may influence the mechanisms of action of AXT. It is unlikely that this disparity 
in neuroprotection is due to changes in AXT’s antioxidant capacity, but it is possible that AXT is 
no longer efficacious at this dose, in the aged environment, because oxidative damage has been 
accumulating over time. Mamun Al-Amin et al. 2015 demonstrate that age does impact the 
efficacy of AXT in the brain’s endogenous antioxidant systems. These authors assessed the levels 
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and activity of antioxidant enzymes across major brain structures in young and aged animals. They 
illustrate that AXT was more beneficial in fortifying the endogenous antioxidant system in young 
brains, while this effect was blunted in the aged microenvironment [90]. It is also likely that the 
lack of neuroprotection against loss of TH in the aged animals is directly related to the age related 
changes of microglial activity and response to the MPTP. It has been established that microglia 
become primed in the aged environment, and not only demonstrate higher activation at baseline, 
but are also simultaneously hyper responsive to stimuli and resistant to the regulatory signals to 
restore microglia function to a physiological state [15]. The later may explain why we do not 
observe a reduction in microglial activation with AXT in the aged animals. MPTP is a very potent 
neurotoxin and it rapidly produces a dramatic lesion (a frequent criticism of this model), thus, it 
does not accurately represent the time course and degree of neurodegeneration that occurs in the 
human condition. Aged animals are thought to be more susceptible to this toxin, therefore, it is 
possible that this is not the best suited animal model of PD to fully elucidate the therapeutic 
potential of AXT in an aged population. Given that the aged microenvironment is more sensitive 
to CNS insults, it may be better to use a slower acting pathological mechanism to model PD, such 
as the AAV mediated over expression of synuclein. This model may be better to explicate the 
efficacy of AXT, or other natural compounds, in interrupting the interaction of age and the 
pathophysiology of PD. 
In conclusion, we have corroborated our previous findings that AXT is neuroprotective 
against MPTP induced neurotoxicity in young animals. We show that AXT preserves TH in the 
striatum and substantia nigra of young animals exposed to MPTP, but the same protective effect 
for TH was not observed in the aged mice treated with AXT. Interestingly, we did observe a 
neuroprotective effect in the aged mice when we examined anti-NeuN staining, suggesting that we 
could preserve neuron loss but not loss of TH. We establish here that aged animals respond 
 68 
 
differently to both the MPTP toxin and the AXT supplement. This disparity in neuroprotection 
suggests that some of the normal changes that occur in aged animals, are impactful in the response 
to proposed novel therapeutic compounds. Given the parallel changes in SNpc neurons in both 
normal aging and in Parkinson’s disease, it has been postulated that aging creates a “pre 
parkinsonian state”. This concept is highly impactful, because it suggests that only using young 
mice to model PD pathology ignores a vital contributing element that drives the disease process in 
the human conditions. By using aged animals, we capture a more realistic physiological 
environment that includes an underlying vulnerability. Ultimately, investigating these pathological 
mechanisms in an aged mammalian system should increase translatability of preclinical findings 
into useful medications or treatment strategies. Future studies are needed to further assess the 
disparity in AXT neuroprotection in young and aged animals. It is possible that AXT was less 
efficacious in aged animals simply because of the dose used. It is possible that aged animals require 
a higher dose in order to prevent the robust microglial activation and oxidative stress that occurs 
after MPTP. Additionally, there may be other physiological changes brought about during the 
normal aging process that effect how AXT functions. Given that we observed a treatment effect of 
AXT in preserving neurons but not TH, it is likely that the time points in our experiment did not 
include the full recovery from the MPTP insult in the aged animals. It is possible that we may see 
an improvement in TH levels with AXT treatment if the recovery time was extended.   
 
Abbreviations: PD, Parkinson’s disease; AXT, astaxanthin;  MPTP, 1-methyl-4-phenyl-1,2,3,6-
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Chapter 4 
Astaxanthin supplementation modulates cognitive function and 
synaptic plasticity in young and aged mice 
4.1 Introduction 
 Aging is a prominent predisposing factor for many of the neurodegenerative disorders, and 
is associated with cognitive decline among a subset of the elderly. During the aging process there 
are multiple physiological changes, many of which lead to the loss of tissue integrity and organ 
function. These age related changes of the brain can also lead to cognitive dysfunction, presenting 
as difficulties in memory, attention, and executive function in some aged individuals [129]. The 
precise molecular mechanisms that contribute to cognitive impairment are still under investigation. 
However, it is understood that neuroinflammation and oxidative stress, proteostaisis and 
mitochondrial function are major biological processes that are negatively affected during the aging 
process [48]. Dysfunction in these basic cellular functions can contribute to cognitive decline in 
aging and neurodegeneration. The incidence of neurodegenerative disease and other age related 
disorders are expected to increase dramatically as the largest sector of the population gets older. 
This increased prevalence is associated with a drastic economic burden, therefore developing 
strategies to manage these age related medical issues is of great public health interest [130].   
Carotenoids have been investigated for their impact on human health; one carotenoid that 
has gained significant attention recently is the xanthophyll astaxanthin (AXT). AXT has been 
investigated for a potential therapeutic role in various clinical conditions, notably cardiovascular 
disease, metabolic syndrome, athletic performance and cancer [42, 86, 91]. Interestingly, while 
these conditions are diverse, they do share common features of oxidative stress and inflammation, 
both of which are known to increase with age and contribute to neural dysfunction. AXT has been 
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used therapeutically in models of neurodegenerative disease and neuronal injury. AXT treatment 
was found to mitigate cytotoxicity from amyloid β fragments in vitro, and this increased cell 
survival was associated with an AXT mediated interruption of the apoptotic cascade and calcium 
dysregulation [47, 131, 132]. AXT attenuated neurotoxicity in an in vivo model of Parkinson’s 
disease [118]. AXT treated animals were also protected from the hippocampal damage in an 
amygdala kindling model of epilepsy [92], from aluminum chloride toxicity [37] and in traumatic 
brain injury [39]. These observations establish that AXT has a neuroprotective effect against 
pathological conditions.  However, emergent evidence from recent work suggests that AXT may 
also have the capacity to increase neurogenesis and neural plasticity and may therefore play a role 
in modulating cognitive function. Yook et al, 2016 demonstrate that AXT treatment can increase 
stem cell proliferation in the hippocampus and this was associated with improved spatial memory 
in adult mice [77]. It has been shown that consumption of AXT may increase brain derived 
neurotrophic factor (BDNF) [81, 133], and important growth factor for neural development, 
growth and function [134].  
 A few studies have reported that AXT can improve aspects of cognition, although this is 
most frequently attributed to a neuroprotective mechanisms in animal and cellular models of 
neurodegenerative disease and neural injury [38, 39, 133]. Given that symptoms of cognitive 
dysfunction are also seen in some elderly individuals during normal aging, it is possible that AXT 
treatment may be effective in rescuing the age related cognitive decline in non-pathological 
conditions. However, relatively few studies have assessed the effect of AXT on cognitive function 
in normal, healthy mice, while the impact of AXT on the aged CNS has been largely ignored. 
Here, we investigate the potential for AXT to modulate cognitive function and synaptic plasticity 
under physiological conditions in both young and aged mice.  
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4.2 Materials and Methods 
All procedures were conducted according to the National Institute of Health Guide and Use 
of Laboratory Animals and the University of South Florida IACUC. Male C57BL/6J were used in 
these studies at both 3 and 18 months of age. Animals were housed in groups of 4 and maintained 
in controlled conditions of 21⁰C and a 12 hr light/dark cycle.  
 
Table 4: A schematic representing the time points of experimental procedures relative to the 
treatment with astaxanthin.  
 
 
Dietary treatment: Mice were treated with a natural astaxanthin supplement sold as Bioastin®, 
generously donated to the lab by Cyanotech Corporation. This material was incorporated into a 
Harlan Teklad rodent diet to achieve a dose of 30 mg/kg bodyweight. Because Bioastin® is a 
product that contains a relatively high volume of inactive ingredients such as cellulose and gelatin, 
we included an additional dietary condition where mice were fed equal concentrations of the 
Bioastin® product without astaxanthin as a vehicle control. However, we have previously shown 
that the vehicle condition does not have an effect in other experiments, and it is unlikely that the 
inactive ingredients should effect the endpoints in this study. These compounds were delivered to 
the mice by an experimenter 3x per week in order to ensure the freshness of the food and test 
compounds. Diets were available ad libitum for 1 month prior to behavioral analysis. In order to 
confirm that the mice were consuming the enriched diets, research staff regularly recorded the 
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food intake per cage and body weight of the mice and did not observe any significant differences 
in weight gain over the course of the experiment due to the dietary treatments. 
Behavioral Testing 
Novel object Novel Place - This test is a useful tool to evaluate spatial memory and recognition 
in rodents. Mice were allowed to explore a moderately lit arena (40cm x 40cm) for 15 minutes 24 
hours prior to training in order to habituate the animals to the test environment. Mice were placed 
back in the arena the next day and allowed to explore two identical objects for a 5 minute 
familiarization trial, before being placed into a holding container for a 10 minute intertrial interval. 
The familiarization phase consisted of three of these training trials. Mice were returned to the home 
cage for one hour then returned to the test chamber. The testing phase included one familiar object 
and one novel object that was placed in the opposite corner of the chamber. Animal behavior was 
recorded using ANY-maze software (Stoelting) and test videos were evaluated for time interacting 
with either the familiar or novel object. Data was collected by an experimenter blind to treatment 
conditions.  
Fear conditioning- Hippocampal function and memory formation was further assessed by training 
the mice to associate a 90db tone presented for 30 seconds and co-terminating with a 0.5mA foot 
shock. 24 hours after training, mice were put back in the training chamber without exposure to the 
tone and shock, and freezing behavior was monitored for three minutes. Freezing was operationally 
defined by no activity for 2 seconds. Freezing behavior was also monitored in an altered context 
paradigm. Briefly, mice were placed to a novel environment and allowed to explore for three 
minutes before being exposed to the same 90db training tone for the remaining three minutes of 
the test. Animal behavior was recorded and monitored by ANY maze software (Stoelting). 
Freezing behavior in response to the conditioned stimulus was evaluated and presented as a 
percentage of the time freezing relative to the beginning phase of the test without the tone.    
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Radial arm water maze - In order to investigate spatial memory, mice were trained for 8 trials 
per day for 2 days to locate a hidden platform (submerged in approximately 2 cm of water) in one 
of six arms. Throughout the testing, the pool water was maintained at a temperature of 23 degrees 
Celsius. During the first day of training, mice were placed in pool and allowed to search for a 
clearly visible platform or a submerged, hidden platform every other trial in order to acclimate the 
animals to the concept of locating a hidden platform. On the second day of training, the mice 
searched for only the hidden platform. Trials were terminated when the mouse successfully 
escaped the maze by climbing onto the platform or after one minute. During the training phase, 
the mice were allowed to rest on the platform for 30 seconds at the end of each trial to reinforce 
the spatial orientation of the large spatial cues (paper cut outs of basic geometric shapes) placed 
on the walls around the maze and the escape behavior. To test perseverance and mental flexibility, 
the mice were required to relearn the location of the platform on day three. The platform was 
moved to the arm 180 degrees from the previous training location. Videos of all trials were 
reviewed by a researcher blind to the treatment conditions and evaluated for both the latency to 
find the platform, defined as latency and the number of errors made during the navigation of the 
maze. Errors were defined as entry into an incorrect arm by half of a body length. Errors were also 
recorded if the animal partially exited an arm and immediately re -entered, or was immobile for 
approximately 5 seconds.    
Electrophysiology- Mice allocated to electrophysiology were rapidly euthanized immediately 
before 400μm sections were prepared by vibratome. Hippocampi were carefully dissected out of 
the sections and allowed to recover in the recording chamber for an hour before experimentation. 
Field recordings (fEPSP’s) were generated by stimulating in the CA3 Shafer Collaterals, and 
collected from the stratum radiatum of the CA1 with a glass microelectrode filled with artificial 
cerebrospinal fluid and impedance between 1-5 mΩ. After placement of electrodes and stable 
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responses were observed from each slice, the input/output relationship was established by 30 
repeated stimulations from 0-15mV, steadily increasing stepwise by .05mV. The following 
experiments were conducted using the stimulus determined to evoke an EPSP of approximately 
50% of the max response. Paired Pulse Facilitation (PPF) was used to evaluate the pre synaptic, 
short term responses by delivering 2 stimulations every 20ms, where each subsequent pair of 
stimuli was separated by an additional 20ms (up to 300ms). Long term potentiation was evoked 
using a theta burst protocol, and waveforms were evaluated for the change in slope of the fEPSP’s. 
Immunohistochemistry- Brains were fixed with 4% paraformaldehyde for 24 hours then incubated 
in a 30% sucrose solution for three days to protect the tissue from cryo-damage during sectioning. 
40 m thick sagittal sections were prepared on a cryostat and selected every 6th section for all IHC 
procedures. This periodicity allows consistent sampling of the structure, although extra sections 
medial and lateral of the hippocampus were also included to ensure thorough investigation of the 
entire region. Free floating sections were blocked in 10% serum before being incubated in primary 
antibody (KI 67, Jackson Chemicals 1:500; Doublecortin, Santa Cruz 1:200,  IBA 1, WAKO 
Chemicals 1:2,500). Primary antibodies were diluted in PBS containing serum and Triton X-100 
overnight at 4oC while the sections were incubated in biotinylated secondary antibody for 60 
minutes at room temperature. Avidin-biotin complex (Vector Labs) was used to increase substrate 
formation from the precipitation reactions were developed with diaminobenzidine (Sigma-
Aldrich).     
Quantification: Estimated population was determined using the optical fractionator probe and 
unbiased stereological methods (Microbrightfield, Cholchester VT). The hippocampus was 
sampled with a counting frame and grid size of 150x150 μm in order to count all of the positive 
cells within the structure of interest because aged animals have substantially reduced neurogenesis. 
IBA 1 was assessed using a digital image analysis program, NearCYTE (nearcyte.org), as 
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previously described [99] [118]. Briefly, we were able to quantify the area of positive IBA 1 
staining by creating high resolution images with the AxioScan microscope (20x objective). Using 
NearCYTE software, regions of interest were applied to the images, then compared to a threshold 
of intensity set by an experimenter blind to treatment conditions. This comparison generates a ratio 
of the number of pixels that match this user defined criteria within the region compared to those 
that fall below the threshold. We have previously determined that data collected with NearCYTE 
and expressed as a percent positive area also reliably and accurately corroborates the data collected 
with unbiased stereology and presented as an estimated population of positive cells within a region 
[99]. 
Data Analysis:  The data presented graphically as the group mean and standard error of the mean. 
Statistical analysis was performed using GraphPad Prism software. 2 Way ANOVA was 
conducted, while Bonferroni multiple comparisons posthoc tests (unless otherwise specified) were 
used to further compare differences between groups. Cued context and radial arm watermaze data 
were analyzed using SPSS statistics 23 software for a repeated measure ANOVA.  
4.3 Results 
AXT modulates synaptic plasticity 
Recent research has generated substantial evidence to establish AXT as a neuroprotective 
agent, while results from the most current studies are just beginning to come together to suggest 
the potential for AXT to have a role in promoting or maintaining neural plasticity to modulate 
cognitive function in healthy animals. Here, we show for the first time that AXT supplementation 
can modulate synaptic plasticity in both young and aged mice. Animals that consumed a diet 
enriched with AXT displayed enhanced early phase LTP induced using a theta burst stimulation 
(TBS) protocol. Both young and aged mice showed increased slopes of the fEPSP’s after TBS 
(Figure 1 A and B). We determined that AXT supplementation alone does not significantly alter 
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the synaptic transmission, as the input/output relationships were similar across experimental 
conditions (Figure 1 C) or change the pre synaptic activity (data not shown). 
 
 
Figure 4.1: One month of dietary supplementation of AXT was able to enhance early phase LTP 
at the CA1-CA3 synapse in the hippocampus. Both age groups that consumed an AXT enriched 
diet demonstrate an increased slope of the fEPSP’s after theta burst stimulation compared to their 
age matched controls. Aged animals treated with AXT (A AXT) show enhanced LTP compared 
to the aged control mice (A CTL). Young ATX supplemented animals (Y AXT) also show 
enhanced LTP compared to the young mice on the CTL diet (Y CTL)  (A), and this trend remains 
significantly different during the last 10 minute of the experiment (B) One way ANOVA; F: 24.72  
**p<0.01  ***p< 0.001. The observed trends in enhanced early phase LTP were not due to direct 
dietary induced alterations of synaptic transmission, indicated by similar relationships between 
stimulus intensity and synaptic response (C) or by short term plasticity mediated at the pre synaptic 
site (data not shown). 
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AXT modulation of synaptic plasticity is not explained by increased neurogenesis 
Yook et al, 2016 demonstrate that AXT treatment was associated with increased 
immunolabeling of BrdU within the subgranular layer of the hippocampus in young mice [77]. 
This suggests that AXT supplementation may have the capacity to stimulate the proliferation of 
neural progenitor cells (NPCs), and ultimately neurogenesis in the dentate gyrus. Given this 
preliminary result, the impact of AXT supplementation on neural growth in both young and aged 
mice was evaluated. This investigation used unbiased stereological quantification of 
immunohistochemical labeling of KI 67 (a marker of dividing cells). As expected, we observed an 
age related decrease in KI 67 positive cells in the subgranular zone, as it is known that stem cell 
proliferation slows dramatically with age. We did not observe a significant increase in NPCs of 
diet treated animals even though we did observe a slight trend towards increased cell numbers 
(Figure 2A). The population of neural progenitors in the dentate gyrus is of interest, in part because 
of their capacity to give rise to neurons. Stem cell proliferation can support the growth of new 
neurons that can be recruited into, and fortify existing circuits in the brain. Given the recently 
reported findings that AXT treatment can stimulate NPC proliferation and upregulate BDNF, a 
molecule important for the structural growth and development of neurons, we also evaluated the 
number of newly differentiated neurons within the subgranular zone of the hippocampus. As 
expected, we measured a significant reduction in doublecortin (DCX), a marker for young neurons, 
in the aged animals. However, the marginal increase in KI 67 was not correlated with a rescue in 
DCX in the AXT treated aged animals. (Figure 2 B). We have determined that AXT 
supplementation also does not significantly increase the differentiation to neurons, and that 
neurogenesis does not explain the increased LTP.  
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Figure 4.2: One month of dietary supplementation of AXT does not significantly alter 
neurogenesis in the dentate gyrus. AXT treatment does not significantly stimulate the proliferation 
of neural progenitor cells in the subgranular zone of the hippocampus (A) or increase the 
differentiation to neuronal lineage in the same region (B). 2 way ANOVA n.s. 
 
AXT does not significantly alter microglial function 
Multiple studies report that AXT treatment can alter the proinflammatory profile both in 
vivo and in vitro, suggesting that AXT may be directly involved in modulating microglial activity 
[32, 36, 43, 97, 100, 120]. This mechanism of action is impactful for the observed effect of 
neuroprotection in models using CNS insults, given the role of microglial activation in 
neurodegenerative disease and injury. Microglia are also involved in synaptic pruning in early 
postnatal periods, and are therefore heavily involved in establishing the neural circuitry in the 
developing brain, as well as sculpt and refine these connections later on [12, 13]. Given the 
relationship between microglial function and neural integrity, microglia morphology and 
activation were evaluated in this model by assessing alterations in IBA 1 expression levels in the 
brain. All microglia express IBA 1 regardless of activation state, although perturbations that 
activate microglia are known to correlate with increased expression of IBA 1, therefore, the 
relationship between IBA 1 expression levels across experimental conditions can elucidate a 
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dietary effect on microglial activity. Digital image analysis of IBA 1 staining indicates that AXT 
treatment does not significantly alter the expression of Iba1 in the hippocampus (Figure 3 A), 
cortex (Figure 3 B), or striatum (Figure 3 C). However, there does appear to be general trends for 
AXT to marginally increase IBA 1 levels in both age groups.  
 
 
Figure 4.3: Consuming a diet enriched with AXT does not significantly alter the expression of 
IBA 1 in the hippocampus (A) cortex (B) or striatum, (C). 2 way ANOVA n.s. 
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AXT modulates cognitive function  
AXT supplementation improves performance in cognitive behavioral tasks. One month of 
consuming a diet enriched with AXT improved recognition of the novel object in the novel object 
recognition task. This task exploits rodents’ innate curiosity and propensity to explore new stimuli 
in the environment; exploration time will decrease with repeated exposure to an object as animals 
become more familiar with that object. Test videos were hand scored by an observer blind to 
experimental conditions and evaluated for time interacting with each object. We observed that 
animals that consumed the AXT enriched diet show increased preference for the novel object 
during the testing phase, as they spent more time interacting with the novel object than the familiar 
one presented during the training phase (Figure 4  A and B, respectively). This preference for 
novelty is evident in both the young and aged mice, indicating that the AXT supplementation 
improved short term recognition memory regardless of age. These trends did not seem to be 
influenced by locomotor activity around the chamber during the test (Data not shown).   
 
Figure 4.4: One month of consuming a diet supplemented with AXT increased time of interaction 
with the novel object (A). One way ANOVA p<0.001; F:4.436. 2 tailed T tests *p<0.0.5. The 
exploration of the familiar object was similar across all experimental conditions (B). One way 
ANOVA: n.s. This dietary effect on increased recognition of the novel object is apparent in both 
young and aged animals, although not due to alterations in locomotor activity around the test 
chamber (data not shown).  
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 AXT supplementation lead to a behavioral improvement in the 24 hour contextual fear 
conditioning, a test that indicates hippocampal function and associative memory. Freezing 
behavior was monitored during the course of this training event and was comparable across 
treatment conditions by the end of the training (Figure 5 A). 24 hours later, the mice were re-
exposed to the training chamber without the tone, and freezing behavior was evaluated as a gauge 
of associating the environment with the aversive training stimuli. Aged animals that were treated 
with AXT displayed more freezing behavior to the training environment, indicating that they had 
a better memory of the aversive training events compared to their aged matched controls. We only 
observed an AXT mediated improvement for contextual memory in the aged animals; the young 
AXT treated mice demonstrated similar freezing behavior to the context compared those who 
consumed the standard NIH diet. Interestingly, we observed a dietary effect in the cued context 
paradigm. Animals were placed in novel environment and allowed to explore before being exposed 
to the training tone, representing two distinct 3 minute phases of the test. An increase of freezing 
behavior to the tone indicates an association of the tone and foot shock retained from the training 
event; the formation of the fear memory is a process also largely mediated by the amygdala [135]. 
We observed an overall dietary effect of AXT supplementation increasing the freezing response 
to the tone, evident in both age groups. However, in agreement with the contextual fear 
conditioning, the effect was only significant in the aged animals, reiterating that AXT rescues an 
age related deficit in fear associative learning but does not augment this cognitive process in the 
young (Figure 5 B). Age mice show a heightened freezing response after the first presentation of 
the tone during fear conditioning training. This age related discrepancy normalizes by the end of 
training. During the 7th minute of training, experimental groups show comparable freezing 
behavior and there is no significant impact of AXT on acquisition in either age group (Figure 5 
C).    
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Figure 4.5: One month of dietary supplementation of AXT improves the memory retention of 
aged mice in the 24 hour fear conditioning paradigm, indicated by increased freezing behavior in 
response to the environment where they previously experienced aversive events (A) 2 way 
ANOVA, dietary effect *p<0.05 F: 1, 89. Two tailed T test, **p<0.01. Both young and aged mice 
treated with AXT show an improved performance in the altered context paradigm, demonstrating 
an increase in freezing behavior to the presentation of the conditioned stimulus compared to the 
freezing behavior in the first phase of the test before exposure to the tone associated with the foot 
shock. However, the effect is only significant in the aged animals (B) Repeated measure ANOVA, 
*p<0.05. Aged animals show more freezing behavior compared to the young during training. 
However, by the end of the training, mice show a comparable freezing response and there is no 
discernable influence of AXT on the learning curve (C). One way ANOVA of the percent freezing 
during the last minute of training indicates no significant interaction. 
 
 Mice were trained to locate a hidden platform in a 6 arm arena over the course of 8 trials a 
day for 2 days. Animals were allowed to navigate the maze for a maximum of 60 seconds, and 
their behavior was analyzed for the number of errors made during navigation (entries into an 
incorrect arm) and the time the mice spent searching for the platform (latency). AXT treated mice 
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made similar amount of errors compared to their aged match counterparts in both age groups 
during training (Figure 6 A and B). AXT supplementation did not impact the latency to locate the 
platform during training (Figure 6 C and D). Overall, AXT treatment did not seem to increase the 
efficiency of learning platform location in either the young or aged mice. The animals were then 
tested to relearn a novel location of the platform, positioned 180 degrees from the previous positon 
the platform was located in throughout the training trials. We observed a minor difference between 
age groups regarding how quickly the mice were able to relearn the novel location of the platform. 
Age mice show both slightly increased errors and longer latency (Figure 7 A and B) over the 8 
trials of the reversal test. We did not observe a significant dietary effect in improving efficiency in 
locating the platform during the reversal phase of the test in either the young or aged mice. 
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Figure 4.6: One month of AXT supplementation does not significantly improve learning in the 
radial arm water maze. Both young and old mice treated with AXT show similar efficiency of 
learning the platform location compared to mice that were fed a control diet, as each group made 
similar number of errors during both day one (A) and day two (B) of training. Latency to locate 
the platform did not differ substantially between treatment groups. AXT treatment did not decrease 
latency to locate the platform during day one (C) or day two (D) of training. Repeated measure 
ANOVA n.s 
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Figure 4.7: One month of dietary supplementation of AXT was not sufficient to improve 
behavioral performance in the radial arm water maze task. There is a trend for age mice to show 
increased errors (A) and a longer latency (B) to locate the hidden platform throughout the reversal 
trials compared to young mice. However, there was no improvement in the age matched 
counterparts that consumed the AXT enriched diet. Repeated measure ANOVA n.s. 
 
 Discussion 
AXT has steadily gained attention for a potential therapeutic role in neurodegenerative 
disease. There are numerous reports to establish that AXT treatment is effective at protecting 
neurons from various CNS insults in models of specific neurodegenerative disorders and neural 
injury [36, 37, 39, 118], while there are relatively few studies investigating the benefit of AXT in 
the healthy or aged CNS [43, 97]. Here we investigate the capacity of AXT to modulate cognitive 
function in young and aged mice. We show for the first time that AXT supplementation enhances 
synaptic plasticity at the CA1-CA3 synapses of the hippocampus in both young and aged animals. 
This observation is noteworthy because we expected to only see a rescue of synaptic function in 
the aged animals, as ageing is associated with deteriorating synaptic plasticity. In contrast, young 
animals do not suffer from impaired synaptic plasticity, yet AXT supplementation was able to 
improve LTP compared to their age matched counterparts who consumed the CTL diet. This 
suggests to us that AXT may have a direct mechanism of action in facilitating LTP, in addition to 
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the anti- inflammatory and antioxidant properties that have been the overwhelming focus of studies 
investigating the therapeutic potential of this molecule in various diseases. We did not observe that 
the presence of AXT modulates synaptic transmission on its own, evidenced by similar 
relationships of stimulus intensity (input) to synaptic response (output) across experimental 
conditions. We also did not observe significant differences in the pre synaptic activity (PPF). These 
findings suggest that AXT supplementation is likely exerting its action on facilitating long term 
potentiation in the post synaptic signaling cascades that promote calcium influx and ultimately 
lead to increased insertion of AMPA receptors into the post synaptic membrane. To date, it is 
unclear if AXT is directly acting on downstream signaling cascades that regulate calcium signaling 
or AMPA receptor modulation, but there are numerous studies that report changes in signaling 
pathways that are known to play a role in early phase LTP [32, 38, 47]. Currently, these reports 
are only correlative, however provide support for a post synaptic mechanism being altered by the 
presence of AXT that is responsible for increasing LTP in our treated animals. Future studies 
should thoroughly examine the post synaptic mechanisms that underlie these observations of 
enhanced LTP.  
It is interesting to note that an AXT mediated effect of increasing neurogenesis was not 
observed in this study, as hypothesized. It has been shown that AXT treatment can stimulate 
cellular division of neural progenitor cells in the dentate gyrus, and that consumption of AXT is 
associated with increased levels of BDNF. Therefore, it was hypothesized that a diet enriched with 
AXT would promote the proliferation of neural progenitors and be associated with increased 
differentiation of (doublecortin positive cells) new neurons in this region. However, our 
stereological estimates revealed that while AXT may slightly increase the number of KI 67 positive 
progenitor cells in the hippocampus, it did not lead to notable increases in the number of new 
neurons in the same regions. Our electrophysiological data confirms that, in fact, dietary treatment 
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of AXT is likely not functionally increasing the number of new neurons or active synaptic 
connections in the hippocampus, as the input/output curves of diet treated and control conditions 
are similar in both age groups, suggesting that there are comparable number of active synapses in 
the field that contribute to the fEPSP. This observation is notable because previous reports 
regarding possible mechanism of action of AXT in studies that assess neuroprotection and 
neurodegeneration all come together to suggest likely neurogenic, structural changes, even at the 
level of the synapse as a viable mechanism for AXT to preserve neural integrity and cognitive 
function. However, our data does not support the capacity of functional structural changes, 
evidenced by observations in KI 67 and doublecortin staining, and the input/output relationship 
assessed by electrophysiology.  
Many studies establish anti-inflammatory properties of AXT [32, 38, 97, 100, 106, 120]. 
Given the role of neuroinflammation in neurodegeneration, and the role for microglia in 
maintaining synaptic connections, we assessed the impact of AXT on gross microglial morphology 
by measuring immunoreactivity to IBA 1. IBA 1 is a protein expressed on the cellular surface of 
all microglia. While this marker will label all microglia, these cells are known to upregulate this 
protein when they respond to various insults. Therefore, the relative expression of IBA 1 can 
indicate differences in microglial activity across the diets and ages of animals used in our study. 
We did not detect significant age related or diet related changes in gross microglial morphology. 
Aging is known to increase microglial activation and is associated with an upregulation of IBA 1 
and can relate to gross morphological changes that typically correlate with microglial function 
[136]. However, based on our digital image analysis of immunoreactivity to IBA 1, AXT does not 
significantly alter the expression of IBA 1 in the hippocampus, cortex or striatum. It is possible 
that our animals were very healthy and as yet did not display age related alterations of microglial 
activity. However, it is also possible that AXT is modulating microglial function in subtle ways 
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that do not influence over all morphology that would be detected in the image analysis software. 
Future studies should focus on precisely characterizing the impact of AXT on microglial 
physiology.  
Our data suggests that mice treated with AXT show improved performance in hippocampal 
dependent behavioral tasks. We observe an improvement in spatial and recognition memory in the 
novel object/novel place recognition tests. Furthermore, we observed similar trends in both young 
and aged mice, suggesting that AXT treatment both rescued the deficit for exploring the novel 
object in the aged mice, but also improved recognition in the young mice even above and beyond 
the young counterparts. As stated previously, the capacity for AXT to enhance learning and 
memory in the young animals is a novel finding that suggests a direct mechanism of action in 
neural plasticity.  
We also observed a behavioral improvement in fear conditioning. As expected, aged 
animals that consumed the standard rodent diet demonstrate impaired recall of the fear associated 
memory of the aversive events they encountered during training. This impairment is evident in the 
aged mice on the control diet displaying less freezing behavior in the 24 hour contextual fear 
conditioning test than the young control mice, who typically do not suffer from any learning or 
memory impairment. In contrast, the AXT enriched diet seemed to rescue the age related memory 
deficit. Aged animals that were fed the AXT supplemented diet show better retention of the fear 
related memory foot shock, and freeze more during exposure to training context. The association 
of the aversive events with the training context is a process mediated by the hippocampus; this 
effect indicates that AXT treatment is associated with improved hippocampal function in aged 
animals.  
We also observed a behavioral improvement in the altered context paradigm, in which the 
trained animals are exposed to a novel environment and presented with the same training tone that 
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was presented preceding the foot shock during training. In this paradigm, all sensory cues except 
the training tone are altered, so that the only stimuli the animals are likely to associate with the 
fear conditioning training is the specific tone. In these experiments, mice from all experimental 
conditions show minimal freezing to the altered context before the presentation of the tone. These 
results were expected, as there should have been no negative associations formed to any of the 
stimuli presented in the novel context, except for the training tone. Interestingly, there is a main 
effect for the AXT supplementation to increase freezing behavior to the conditioned stimulus in 
both young and aged mice. However, the effect is only significant in the aged animals, reflecting 
the AXT mediated rescue of an age associated of a cognitive deficit, similar to the trends observed 
in fear conditioning. The formation of this fear associated memory is a process that is mediated by 
the amygdala and may be indicative of another cognitive domain affected by AXT 
supplementation.    
There was no dietary effect in the radial arm water maze, although this is also a 
hippocampal, spatial memory dependent task. Aged animals learned more slowly in the reversal 
phase of the test, but AXT treatment did not rescue the impairment. This may be because the aged 
animals in this study were not significantly impaired, and still learned the task relatively well. 
Therefore there was no opportunity for restoration of an age related deficit, as was observed in fear 
conditioning. It is also interesting that we observed a dietary treatment in both young and aged 
mice in the novel object novel place recognition task, which is also partially dependent on 
hippocampal spatial memory. It is possible that AXT is exerting an effect on another structure, 
such as the perirhinal cortex that is also involved in the novel object task [137, 138].  
 In conclusion, AXT treatment may have a direct role in modulating synaptic plasticity in 
the hippocampus. Here we show that enhanced synaptic plasticity is a mechanism of action of 
AXT that underlies some of the improved performance on hippocampal dependent tasks.  
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Abbreviations: AXT, Astaxanthin; BDNF, brain derived neurotrophic factor; LTP, long term 
potentiation; fEPSP field excitatory post synaptic potentials; PPF paired pulse facilitation; DCX, 
double cortin; NPC, neural progenitor cell; IBA1 ionized calcium binding adaptor protein; 
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Chapter 5 
Discussion 
 
Parkinson’s disease is common neurodegenerative disease that disproportionately afflicts 
the elderly. The current treatment strategy is largely palliative; there are currently no available 
medications that stop neurodegeneration. Therefore, this disease is associated with a substantial 
economic burden that is expected to raise steadily with the exponential increase in the aged 
population [1, 130]. Making progress towards successful management of Parkinson’s disease in 
patients requires identifying novel therapeutic agents that are ideally capable of interrupting the 
processes that lead to cell death or even facilitate restoration of the neuron loss in the nigro-striatal 
pathway. Determining which compounds will most likely be advantageous for PD also necessitates 
a better understanding how the pathological processes that underlie neurodegeneration work in 
concert to precipitate cell death. Currently, these biological mechanism are still being elucidated, 
and the incomplete understanding of their interactions is likely a hindrance to the successful 
translation of promising compounds in basic research to clinical trials.   
AXT represents an intriguing candidate as a potential therapeutic agent in the treatment of 
PD. AXT is traditionally known for its antioxidant properties, and has been marketed for this 
benefit for years. Perhaps this explains the disproportionate focus on the antioxidant mechanisms 
of AXT across experimental models in the literature. Many studies report reduced oxidative 
damage across experimental models [36-38, 46, 81, 90, 93, 94, 98, 100]. However, recent research 
has focused on this molecule as a potential treatment in a variety of conditions and spans multiple 
model organisms. Thus, empirical evidence has begun to elucidate diverse biological activities, 
including anti- inflammatory properties [38, 97, 106, 120] and the capacity to augment 
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mitochondrial function [33, 34, 43, 55, 98]. These reports suggest that the bioactivity of AXT may 
directly oppose multiple pathological mechanisms that underlie the neurodegeneration in PD. For 
example, neuroinflammation, oxidative stress and mitochondrial dysfunction are all well 
documented pathological processes that are related to cell death in PD [9]. Many compounds have 
demonstrated neuroprotective properties in animal models of PD. Interestingly, many of the failed 
clinical trials use agents that only address one disease mechanism. For example, historically there 
has been a great deal of attention on using antioxidants to mitigate neurodegeneration in PD, but 
many of these have proven useless in clinical settings. This is likely because oxidative stress, 
although clearly involved in cellular stress, is not the only or most significant pathological 
mechanism behind the disease. Compounds such as glutathione have shown promise in animal 
models of PD, but have not translated into viable medications for PD [139]. Similar antioxidant 
compounds, such as N-acetylcysteine, have not surpassed phase II clinical trials. Therefore, 
focusing on alleviating a single stressor does little to slow cell death in this context and the 
avocation for antioxidant based therapies in PD has become a worn out conversation.  
Alternatively, the failure rate of compounds that target single mechanisms highlights 
another provocative concept. While it has been established that there are multiple biological 
processes impacted during the pathogenesis of Parkinson’s disease, the exact molecular 
mechanisms that precipitate cell death are still somewhat debated. However, impairment in any 
vital biological process will cause downstream dysfunction that further impairs cellular 
physiology. It is important to consider that each pathological mechanism involved in PD can 
interact with and exacerbate deteriorating cellular processes. For example, widespread microglial 
activation in the substantia nigra will release reactive oxygen species that promote the aggregation 
of alpha synuclein [26]. Alpha synuclein aggregation also stimulates microglial activation and 
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disrupts mitochondrial function [3, 25, 50, 56], which promotes the release of additional reactive 
oxygen species, creating a detrimental feedforward loop.  Furthermore, aging is correlated with 
increased microglial activation, oxidative stress, and impaired proteostaisis. As described by 
Reeve et al, 2010 the normal aging process exacerbates this cycle, independently driving forward 
each of the proposed pathogenic processes simultaneously [6]. AXT may be especially efficacious 
in the context of PD because it seems to have a broad range of biological activities. Extrapolating 
from the literature, it seems that AXT can attenuate multiple pathogenic targets and reduce some 
of the detrimental interactions that feedforward, creating an inhospitable environment in the 
substantia nigra for dopaminergic neurons.  
AXT as a therapeutic target is impactful for the field because of the ways it can be 
employed to treat Parkinson’s disease. This compound is widely available and generally regarded 
as safe. No adverse events have yet been attributed to AXT supplementation. It is possible that this 
compound could be taken for years as an adjuvant therapy alongside normally prescribed PD 
medications. However, this would be contingent on further testing to confirm the complete absence 
of drug interactions- although to date, drug interactions have not been reported. It is also possible 
that AXT may prove to decrease lifetime risk of developing PD. There are certain individuals that 
may be identified as at risk for developing PD, such as those with genetic mutations or that have 
been exposed to agents associated with Parkinsoniansim. These patients may benefit from long 
term use of AXT. However, our experimental design does not directly suggest that AXT would be 
useful in preventing neurodegeneration before an insult. The animals in our experiment were pre-
treated with AXT before the administration of MPTP. This paradigm suggests that AXT blocks 
the neurotoxicity of the drug, which is an exciting and promising result. However, one criticism 
of this work is that patients have already suffered dramatic cell death by the time they are 
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diagnosed with PD. Identifying novel therapeutics that can restore cell loss would be ideal. 
Therefore, it would be interesting to repeat these studies and administer MPTP before the AXT 
supplementation and monitor re innervation of dopaminergic terminals to the striatum. Results of 
this nature would be more impactful for the patients suffering from extensive neurodegeneration.  
The pretreatment of AXT in our experiments brings about another caveat: the potential 
interference of AXT in the conversion of MPTP to MPP+. MPTP is not directly toxic on its own, 
but is broken down by monoamine oxidase B into a highly toxic metabolite MPP+. Our 
experiments did not confirm whether or not AXT treatment can affect the conversion rate into the 
bioactive compound and it is possible, but unlikely that our dietary effects could be due to reducing 
the presence of MPP+ in the CNS to begin with. We were unable to verify a dietary effect of MPP+ 
levels in our brain samples, as our experiment was conducted over 7 days; the half-life of MPP+ 
is only a few hours. Additional, separate experiments would need to be done in order to answer 
this question. However, it has been demonstrated in cell culture experiments that AXT can prevent 
cell death from MPP+ in vitro, indicating that AXT can mitigate cytotoxicity specifically from the 
metabolite [34, 57, 58, 98]. Furthermore, our results suggest that there is still AXT mediated 
neuroprotection after neurotoxicity. This is evident in the aged animals treated with both AXT and 
MPTP. Aged mice treated with MPTP show significant loss of TH immunoreactivity in both the 
striatum and substantia nigra. AXT treated animals were not protected from the reduction of TH 
in either brain region. However, upon further investigation, we can see that aged animals 
supplemented with AXT before the MPTP injection do show a retention of NeuN in the SNpc. 
This observation suggests that the neurons in this region survived the MPTP neurotoxin and may 
recover the TH loss in time.  
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Another caveat is the MPTP model itself. It would be interesting to test this compound in 
other models, such as an alpha synuclein over expressing model. Generally, this model is 
considered to more closely represent the pathology as it occurs in humans, as the pathology 
progresses considerably slower than toxin based models. The presence of synuclein aggregates 
represents another impaired biological process that further perpetuates the disease process. It 
would also be responsible to examine AXT in genetic knockout models, as genetic mutations can 
lead to early onset, rapidly progressing forms of PD. For example, genetic models based on 
mutations of PTEN induced putative kinase 1 (PINK), includes elements of mitochondrial 
dysfunction in order to better elucidate the impact of AXT on mitochondrial dysfunction. This 
possibly represents a major mechanism of action, because mitochondrial dysfunction is intimately 
tied to Parkinson’s disease as well as other neurodegenerative disorders. However, while there is 
some indication in the literature that AXT does work at the level of the mitochondria, the effects 
are still only preliminary. It is difficult to fully extrapolate these trends from the literature, as they 
are generated from diverse experimental settings. Thorough studies investigating this role have not 
yet been conducted and this concept remains preliminary. It would be interesting to examine how 
AXT treated cells respond to insults on a seahorse apparatus, a machine that can analyze cell 
metabolism in real time.   
There is substantial evidence that AXT can modulate the inflammatory response to CNS 
insults [32, 38, 51, 97, 100, 106, 120]. Chapter two evaluates the impact of AXT on microglial 
response to MPTP induced neurotoxicity in young animals. In this experimental design, 3 month 
old mice were treated with a diet enriched with AXT for one month then received intraperitoneal 
injections of MPTP. Animals were allowed to recover for 7 days before tissues were collected for 
biochemical analysis.  Microglial response was assessed primarily through the 
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immunohistochemical analysis of IBA 1 staining in the substantia nigra and the striatum. IBA 1 
labels all microglia regardless of activation state, however these cells will upregulate IBA 1 when 
responding to an insult in the environment. Therefore, differences in IBA 1 expression across 
experimental conditions can indicate how the microglia detect and respond to MPTP and begin to 
elucidate an AXT mediated attenuation of this response. One important consideration in using this 
approach is that IBA 1 is not specific to any microglial function, and the induction of IBA 1 by a 
given insult is usually trivial compared to other markers. For example, CD 68 labels phagocytotic 
vesicles, so this marker reliably indicates phagocytosis. There is typically a much greater 
difference in an insult that leads to upregulation of CD 68 compared to baseline; in contrast, the 
baseline expression of IBA 1 is typically high.  
In this experiment, other markers were investigated to further assess inflammatory status 
after MPTP. CD 68 and MHC class II and for T cells were probed using immunohistochemistry 
and all three of these molecules were detected in very low abundance. Although measuring the 
differential expression in these molecules would have yielded more descriptive information about 
the inflammatory response to MPTP with or without AXT, the expression was too low to 
effectively evaluate. This low threshold was likely due to the extent of recovery that occurred in 
the brains of young animals during our 7 day recovery phase. It has been shown that the 
inflammatory response peaks within a few days, and it is likely that microglia have almost fully 
recovered within our 7 day time frame [121]. Another caveat of this experimental design is that 
the full anti-inflammatory capacity of AXT may have been under represented in this study; it is 
possible that the data captured only a small subset of anti-inflammatory capacity of this molecule 
in this model. If samples were collected to analyze microglia function at earlier time points, this 
study may have detected a larger AXT attenuation of inflammatory events during the peak activity 
 101 
 
of microglial response to MPTP. Furthermore, additional measures of microglial function would 
have been advantageous to fully characterize the impact of AXT on microglial activity in response 
to neurodegeneration, such as a PCR gene array of transcripts associated with either the M1 or M2 
phenotype. Because gene arrays can yield a lot of information, it may be easier to describe the 
nuances of AXT modulation of microglial activity with age and in response to a specific insult like 
MPTP.     
There are normal age related changes in the substantia nigra that reflect the pathological 
characteristics of PD, even without a diagnosis. It has been postulated that aging can lead to a “pre-
parkinsonian state” and aging is recognized as a substantial risk factor in the development of PD 
[49, 116]. Age related changes clearly interact with the pathomechanisms that contribute to 
neurodegeneration and perpetuation the disease process. Despite the significance of the ageing 
process in the onset of PD, the use of aged animal models is under represented in the preclinical 
setting. We have explored the efficacy of AXT in both young and aged animals and show that 
there is an age related disparity in neuroprotection. Young animals treated with AXT show 
retention of TH immunoreactivity in both the nigra and the striatum that correlates with preserved 
neuronal population in the SNpc even after exposure to the MPTP toxin. In contrast, aged animals 
treated with AXT show the loss of TH in the nigra and denervation of the striatum. Reduced TH 
in the nigrostriatal circuitry will lead to impaired dopamine transmission and may still manifest as 
motor dysfunction. However, aged animals that consumed the AXT enriched diet still show a 
retention of NeuN in the SNpc. This suggests that the neurons in the SNpc survived the MPTP 
insult, but may have transiently lost TH immunoreactivity. AXT treatment prevented significant 
cell loss in this area, and it is possible that these animals may have eventually restored the TH 
levels in the substantia nigra. This immunohistochemical data in our experiments represents a 
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snapshot of the brain 7 days after MPTP. It is possible that if we let the aged animals recover for 
a longer period of time, we may have also detected a dietary effect in TH immunoreactivity in the 
nigra and striatum. In this experiment we only assessed a single time point. Future studies may 
examine the time and dose relationship that is necessary to achieve striatal TH preservation that is 
comparable to young. Including additional time points beyond 7 days may elucidate if our 
observations of NeuN retention may lead to TH reinnervation of the striatum in time.  
In chapter 4, we investigate the efficacy for AXT supplementation to modulate cognitive 
function in both young and aged mice. While a few studies report an association for AXT to protect 
cognitive function, most of these were in the context of a particular CNS insult [38, 39, 106]. These 
results reiterate a neuroprotective mechanism of AXT, but on their own do not fully imply that 
AXT has a direct mechanism of action in augmenting cognitive function under normal physiology. 
We show that AXT can enhance early phase long term potentiation in both young and aged mice. 
This is a novel finding that AXT has a direct effect in modulating synaptic plasticity in healthy 
mice. These results were reflected in a behavioral improvement in the novel object recognition 
task. Again, both young and aged animals show an AXT mediated enhancement of novel object 
recognition. Interestingly, we observed a rescue of an age related deficit in freezing behavior in 
contextual fear conditioning and the cued context. Given that we observed improvements in both 
young and aged animals in different cognitive assessments, it is possible that AXT has another 
previously unreported biological activity related to enhancing synaptic plasticity. 
Electrophysiology data reveals that AXT does not directly alter synaptic transmission before theta 
burst stimulation, evidenced by the similarities between the input/output curves across 
experimental conditions. These findings were notable because they indicate that AXT did not 
induce significant structural changes such as synaptogenesis or neurogenesis. There are some 
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reports that AXT treatment increases BDNF and neurogenesis, which may facilitate synaptic 
growth or transmission [81, 133]. AXT also did not drastically alter the short term presynaptic 
plasticity. These findings suggest that AXT is likely acting on post synaptic signaling transduction 
that ultimately increase AMPA receptors at the post synaptic membrane. 
Taken together, these data suggest that AXT is an effective neuroprotective agent with 
multiple biological activities that work in concert to attenuate the neurotoxic cascades that underlie 
neurodegeneration in PD. This compound should be seriously considered for its therapeutic 
potential in the treatment or management of symptoms in PD. Furthermore, AXT may have an 
additional unreported mechanism of action related to enhancing neural plasticity that is evident 
not only in neurodegenerative conditions, but in healthy, normal aging.   
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